Wheatgrass molecules systematic review and meta-analysis ( clinical ) Ai Report.docx

Check the text below is correct, then click Analyse. You can edit it first if the automatic extraction missed something.

This project already has suggested relationships. Analysing again will replace any not-yet-reviewed suggestions, but will keep everything you have already accepted or rejected.

Document text

Study Design
For a systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip if applicable, formulate the core research question using PICO/PECO. Define population, intervention or exposure, comparator, and outcome(s). Explain clinical or scientific rationale, and whether you will register the review (for example, PROSPERO).
For a systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip if applicable, formulate the core research question using PICO/PECO. Define population, intervention or exposure, comparator, and outcome(s). Explain clinical or scientific rationale, and whether you will register the review (for example, PROSPERO). Turn the previous concept into an SOP-style procedure with step-by-step actions, responsible roles, minimum documentation required, and escalation triggers.
For a systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip if applicable, formulate the core research question using PICO/PECO. Define population, intervention or exposure, comparator, and outcome(s). Explain clinical or scientific rationale, and whether you will register the review (for example, PROSPERO). Define quantitative quality indicators and thresholds that will prove this part of the study/review is working. Include how/when each metric is captured and who reviews it.
For a systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip if applicable, formulate the core research question using PICO/PECO. Define population, intervention or exposure, comparator, and outcome(s). Explain clinical or scientific rationale, and whether you will register the review (for example, PROSPERO). Draft the patient/participant communication script or reviewer guidance text that should be read verbatim to maintain consistency and reduce bias.
For a systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip if applicable, formulate the core research question using PICO/PECO. Define population, intervention or exposure, comparator, and outcome(s). Explain clinical or scientific rationale, and whether you will register the review (for example, PROSPERO). List foreseeable operational, ethical, or analytical failure modes in this part of the project and propose mitigation / contingency plans.
For a systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip if applicable, formulate the core research question using PICO/PECO. Define population, intervention or exposure, comparator, and outcome(s). Explain clinical or scientific rationale, and whether you will register the review (for example, PROSPERO). Describe how this part of the project will be captured in regulatory or ethics submissions, including any appendices, audit trails, or notification requirements.
For a systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip if applicable, formulate the core research question using PICO/PECO. Define population, intervention or exposure, comparator, and outcome(s). Explain clinical or scientific rationale, and whether you will register the review (for example, PROSPERO). Explain how digital tools, remote workflows, or decentralized methods will execute this part of the project in low-resource / community settings.
For a systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip if applicable, formulate the core research question using PICO/PECO. Define population, intervention or exposure, comparator, and outcome(s). Explain clinical or scientific rationale, and whether you will register the review (for example, PROSPERO). Translate this part of the design into a training module outline for investigators, coordinators, community health workers, or evidence reviewers.
For a systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip if applicable, formulate the core research question using PICO/PECO. Define population, intervention or exposure, comparator, and outcome(s). Explain clinical or scientific rationale, and whether you will register the review (for example, PROSPERO). Define how this part will be summarized in the final clinical study report or systematic review manuscript so it is publication-ready.
For a systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip if applicable, formulate the core research question using PICO/PECO. Define population, intervention or exposure, comparator, and outcome(s). Explain clinical or scientific rationale, and whether you will register the review (for example, PROSPERO). Identify any data privacy, confidentiality, or IP considerations specific to this part, and describe safeguards.
For a systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip if applicable, formulate the core research question using PICO/PECO. Define population, intervention or exposure, comparator, and outcome(s). Explain clinical or scientific rationale, and whether you will register the review (for example, PROSPERO). Propose timeline checkpoints, gating criteria, and go/no-go decisions specifically for this part before advancing to the next phase.
Core research question (PICO / PECO)
Intervention (PICO formulation): In adults with oral cancer or oral potentially malignant disorders (OPMDs), does local delivery (oral strip/film/lozenge) of chlorophyll or chlorophyllin, apigenin (or flavonoid-rich extracts), quercetin/rutin, or abscisic acid alter clinical, histologic, or biomarker outcomes compared with placebo/no local phytochemical, standard care, or alternative active? HYPERLINK \l "fn1" \h [1]
Exposure (PECO formulation for observational data): Are patients/exposed cohorts using these phytochemicals (any route; focus on local oral delivery where available) at different risk of progression, symptomatic improvement, or biomarker change compared with unexposed patients? HYPERLINK \l "fn1" \h [1]
Population (P): Adults (≥18 years) with oral squamous cell carcinoma (OSCC), oral cavity malignancy, or oral potentially malignant disorders (leukoplakia, erythroplakia, lichen planus with dysplasia), reported in clinical trials, cohort studies, case‑control, or pilot human biomarker studies. Include preclinical/clinical translational sub-analyses focusing on human tissue or human-derived ex vivo models when human trials are absent. HYPERLINK \l "fn2" \h [2]
Intervention / Exposure (I / E): Topical/local oral delivery (oral strip/film/lozenge/mouthwash) or systemic administration of: chlorophyll or chlorophyllin; apigenin (or apigenin-rich flavonoid preparations); quercetin and/or rutin; abscisic acid — alone or in combinations; any standardized extract that lists these as main actives. Dose, frequency, formulation type, and standardization must be recorded. HYPERLINK \l "fn3" \h [3] HYPERLINK \l "fn4" \h [4]
Comparator (C): Placebo / blank strip / vehicle-only, usual care (e.g., surgical/oncologic care without the phytochemical), an alternative active (other phytochemical), or no treatment (observational studies). HYPERLINK \l "fn1" \h [1]
Outcomes (O): Prioritize clinically meaningful and measurable endpoints:
Primary outcomes: lesion size regression, histologic grade change or dysplasia regression, progression to OSCC (for OPMD studies), objective response where applicable.
Key secondary outcomes: validated symptom scores (pain, oral comfort), mucosal toxicity/irritation, local biomarker modulation (NF-κB, COX-2, EGFR, STAT3, MMP-9, oxidative-stress markers), quality-of-life measures, adverse events, and pharmacokinetic/mucosal exposure (if available). Record timeframes (short-term: ≤3 months; medium: 3–12 months; long-term: >12 months). HYPERLINK \l "fn5" \h [5] HYPERLINK \l "fn6" \h [6]
Clinical / scientific rationale
Mechanistic plausibility: Chlorophyllin and chlorophyll derivatives are antioxidants and radioprotective agents that may modulate oxidative-stress—relevant to carcinogenesis; apigenin, quercetin, and rutin have demonstrated anti-proliferative, pro-apoptotic, anti‑inflammatory and anti‑invasion effects in oral-cancer cellular and animal models, frequently modulating NF-κB, EGFR/STAT3, PI3K/Akt and MMP pathways; abscisic acid has emerging signaling roles relevant to cell-cycle and stress responses. Local delivery (oral strip) increases mucosal contact time and local exposure while reducing systemic exposure, improving translational relevance for OPMDs/early OSCC. These mechanisms justify a focused evidence synthesis of clinical and translational outcomes. HYPERLINK \l "fn4" \h [4] HYPERLINK \l "fn6" \h [6] HYPERLINK \l "fn3" \h [3]
Clinical gap: Randomized, well-powered trials of these phytochemicals delivered locally to the oral mucosa are sparse and heterogeneous; a systematic review will consolidate evidence, identify biomarkers for translational studies, and guide formulation/clinical trial design. HYPERLINK \l "fn2" \h [2]
Registration
We will register the protocol prospectively on PROSPERO (recommended fields: title, background, objectives, eligibility criteria, search strategy, study selection, data extraction, risk-of-bias tools, outcomes, analysis plan, and funding/conflicts) prior to screening start; this increases transparency and reduces reporting bias. Use the PROSPERO template and include a clear primary outcome and planned subgroup analyses (formulation type, active, dose, OPMD vs OSCC). HYPERLINK \l "fn7" \h [7] HYPERLINK \l "fn8" \h [8]
SOP-style procedure (step-by-step), responsibilities, and minimum documents
Overview: A reproducible workflow from protocol registration → comprehensive search → screening → data extraction → risk-of-bias → synthesis/meta-analysis → reporting. Each step lists responsible role(s), minimum documentation, and escalation triggers.
Step A — Protocol and Registration (Day 0–7)
Actions: Draft protocol (PICO/PECO, eligibility, outcomes, search strategy, data items, analysis plan), internal review, register to PROSPERO.
Responsible: Lead investigator (Protocol author), Senior methodologist (checks PICO & stats), Regulatory lead (confirms registration fields).
Min docs: Protocol (versioned), PROSPERO submission receipt, conflicts of interest log.
Escalation: If PROSPERO rejects or flags scope issues → meeting within 48 hours to revise.
Step B — Search Strategy & Database Runs (Day 7–21)
Actions: Build search strings (databases: MEDLINE/PubMed, Embase, Cochrane CENTRAL, Scopus, Web of Science, clinicaltrials.gov, CNKI/other regional databases for phytochemicals); include preclinical databases (PubMed Central, animal studies) as prespecified; run grey literature (conference proceedings, theses, patent searches) and hand-search references. Save all searches.
Responsible: Information specialist / librarian (lead), evidence reviewer (backup).
Min docs: Search log (databases, date, exact search strings), initial yield record, deduplication report.
Escalation: If searches return <50 hits across all databases (unexpectedly low) → expand terms/consult domain expert.
Step C — Screening (Title/Abstract; Full text) (Day 22–35)
Actions: Two independent reviewers screen titles/abstracts using Rayyan or Covidence; conflicts resolved by third reviewer. Record reasons for exclusion at full-text screening.
Responsible: Two trained reviewers (screening), adjudicator (senior reviewer).
Min docs: Screening spreadsheets, PRISMA flow draft, inter-rater agreement metrics (kappa).
Escalation: If kappa <0.6 after initial 200 records → retrain reviewers and re-screen sample.
Step D — Data Extraction & Standardization (Day 36–56)
Actions: Use a REDCap/Excel extraction form; extract study ID, design, population, inclusion/exclusion criteria, intervention details (compound, dose, formulation, duration), comparator, outcomes (definitions, timepoints), effect estimates, variance, sample size, funding/source, and risk-of-bias items; extract biomarker methods and results separately. Two independent extractors; consensus process.
Responsible: Data extractors (two), data manager (oversees DB), lead statistician (checks numeric consistency).
Min docs: Extraction form (versioned), raw extraction files, consensus logs, data dictionary.
Escalation: If >10% discrepancies persist across extraction fields → full audit of extraction for affected studies.
Step E — Risk of Bias & Quality Assessment (Day 57–70)
Actions: Apply RoB 2 for randomized trials, ROBINS-I for non-randomized studies, SYRCLE for animal studies, and GRADE for overall evidence certainty. Two independent assessors.
Responsible: Methodologist (lead), two assessors, GRADE lead.
Min docs: Completed RoB worksheets, GRADE evidence profiles, justification notes.
Escalation: If >50% included trials judged high risk → reevaluate meta-analysis feasibility and pre-specify sensitivity analyses.
Step F — Data Synthesis & Meta‑analysis (Day 71–98)
Actions: Decide whether pooling is appropriate (clinical and methodological homogeneity). For continuous outcomes use mean difference or standardized mean difference; for dichotomous outcomes use risk ratios or odds ratios. Use random-effects model by default; perform subgroup analyses (formulation type, active compound, OPMD vs OSCC), meta-regression if ≥10 studies. Assess heterogeneity (I²) and publication bias (funnel plots, Egger test). Predefine thresholds for effect sizes and heterogeneity.
Responsible: Lead statistician (analysis), senior investigator (interpretation).
Min docs: Analysis script (R or Stata), analytic dataset (CSV), forest plots, heterogeneity & sensitivity outputs.
Escalation: If unexplained I² >75% → do not pool; present structured narrative synthesis and consider alternative subgrouping.
Step G — Reporting & Manuscript (Day 99–120)
Actions: Draft manuscript per PRISMA 2020; include methods appendix with full search strategies, extraction forms, RoB tables, and scripts; prepare evidence tables for main and biomarker outcomes.
Responsible: Lead author (draft), co-authors (content), medical writer/editor (formatting).
Min docs: Manuscript draft, PRISMA checklist, data availability statement, protocol link.
Escalation: If journal peer review requests major data queries → maintain audit trail and response log; seek arbitration from senior PI.
Quantitative quality indicators (metrics), thresholds, capture cadence, reviewer
Search completeness: Number of databases searched (target ≥6 biomedical + 2 grey sources) and number of unique hits after dedup (target >200 unique hits for a broad PICO). Captured after Step B by information specialist and reviewed by methodologist. HYPERLINK \l "fn1" \h [1]
Screening concordance: Cohen’s kappa for first 200 abstracts; threshold ≥0.6 acceptable; capture at end of first screening batch; reviewer lead reviews.
Extraction discordance rate: % of fields with disagreement after independent extraction; threshold ≤10%; captured continuously and summarized weekly; data manager reviews.
Risk-of-bias consensus time: Median time (days) to resolve conflicts; threshold ≤5 days; tracked in issue log; methodologist reviews weekly.
Data completeness: % studies with extractable outcome data for primary outcome; threshold ≥50% (if below, pre-specify narrative-only approach); statistician tracks after extraction.
Meta-analysis feasibility: I² and number of comparable studies; threshold for pooling: at least 3 clinically similar studies and I² <75%; captured before analysis by statistician.
Timeliness: Milestone adherence (days vs plan); threshold 80% on-time; project manager reports weekly.All metrics logged in a project dashboard (Excel/REDCap) and reviewed in weekly team meetings; project manager and PI sign off.
Verbatim participant/reviewer communication scripts (for consistency and to reduce bias)
Screening invitation to reviewers (verbatim): "You will independently screen titles and abstracts for inclusion according to the protocol. Please record 'include', 'exclude', or 'unsure' and add brief reason when excluding. Do not consult other reviewers before recording your decision."
Full-text adjudication instruction (verbatim): "If you and the other reviewer disagree, mark 'conflict' and upload the PDF to the shared folder. The adjudicator will review and record the final decision; provide a one-line justification for your vote."
Data extraction guidance (verbatim): "Extract numerical values exactly as reported. If only graphical data are available, use pre-specified digitization methods. Record units and timepoints explicitly. If data are missing, note 'missing' and specify attempts to contact authors (dates)."
Author contact email (verbatim template): "Dear Dr. [Last name], we are performing a registered systematic review on topical phytochemical treatments in oral cancer (PROSPERO ID: [xxxx]). Could you please provide raw outcome data (n, means, SDs) for [outcome name] at [timepoint]? We appreciate a response within 14 days. Regards, [Lead investigator]."
Patient communication (for any prospective pilot or data-use request if contacting participants): "You are being contacted because you participated in [study name]. We are conducting a formal evidence review and may request de-identified results. No personal identifiers will be shared; participation in this review is voluntary."
Foreseeable failure modes and mitigations
Failure: Heterogeneous interventions and outcomes preventing meta-analysis. Mitigation: Predefine narrative synthesis methods and subgroup frameworks; use standardized effect sizes (SMD) when measurement scales differ. HYPERLINK \l "fn6" \h [6]
Failure: Low quality or high risk-of-bias studies dominating the dataset. Mitigation: Use GRADE to downgrade certainty, run sensitivity analyses excluding high RoB studies, and transparently report limits.
Failure: Missing numerical data or unresponsive authors. Mitigation: Use digital extraction from figures, contact authors twice (14-day windows), and proceed with best available data; document attempts.
Failure: Language or regional study access limits. Mitigation: Include regional databases and translators; budget for document translation.
Failure: IP or proprietary data barriers. Mitigation: Use aggregated publicly reported results only; seek data-sharing agreements when necessary; involve legal/regulatory early.
Failure: Reviewer bias or drift. Mitigation: Training sessions, calibration exercises, and monitoring kappa; retrain if concordance falls.
Failure: PROSPERO rejection or scope mismatch. Mitigation: Pre-review PROSPERO guidance and refine title/abstract; if rejected, post initial protocol on institutional repository and note in methods.
Regulatory / ethics capture, appendices and audit trail
Ethics: Systematic reviews of published, aggregated data typically exempt from human-subject review, but if requesting individual participant data (IPD) or contacting participants, obtain ethics approval. Document IRB exemption letter or approval within project folder.
Regulatory: For clinical translation recommendations or if preclinical human biospecimens are used, include a regulatory appendix describing claimed intended use (wellness vs treatment), risk classification, and any country-specific pathways (e.g., FSSAI/AYUSH/CDSCO for India). Include copies of product labelling examples and claim language used in included studies where relevant. [memory: user regulatory focus]
Appendices to include in registration/manuscript: full search strings for every database, data extraction sheet template, RoB forms, GRADE evidence tables, data analysis scripts, PROSPERO registration record, author contact logs, and version-controlled protocol.
Audit trail: Store all versions in a secure repository (institutional Git/Dropbox/OSF) with timestamps and change logs; data manager maintains access log. Include data availability statement and DOI for archived dataset where allowed.
Digital tools, remote workflows, and low-resource execution
Tools: Use Covidence or Rayyan for screening (free tiers available), REDCap or shared Excel templates for extraction, GitHub/OSF for version control and archiving, and R (meta, metafor) for analyses. Use Google Drive/Box for collaborative documents with controlled access.
Low-resource / community settings: Leverage open-source tools (Rayyan web, Zotero for references, RStudio Cloud for analysis). Conduct remote reviewer training via short recorded modules and provide extraction templates in local languages if needed. Use smartphone-enabled PDF access and offline CSV templates for sites with intermittent internet. Assign an on-site coordinator to synchronize uploads weekly.
Data security: Use institutional accounts for storage; encrypt sensitive files; remove participant identifiers before storage.
Training module outline (for investigators, coordinators, community workers, reviewers)
Module 1 — Study rationale & objectives (30 min): PICO concepts and why phytochemical oral strips matter.
Module 2 — Protocol & registration (30 min): How to read protocol and PROSPERO fields.
Module 3 — Searching and reference management (60 min): Constructing searches and saving runs.
Module 4 — Screening & calibration (90 min + practice): Use Rayyan/Covidence; calibration exercises and kappa target.
Module 5 — Data extraction & digitization (120 min): Extraction form walkthrough, digitizing figures, units, and timepoints.
Module 6 — Risk-of-bias tools (90 min): RoB2, ROBINS-I, SYRCLE application with examples.
Module 7 — Basic meta-analysis & interpretation (120 min): Forest plots, I², fixed vs random effects, sensitivity analyses.
Module 8 — Reporting, PRISMA, and manuscript prep (60 min): PRISMA checklist, appendices.
Assessment: Short practical test (screening sample, extraction of one study, RoB scoring). Certificate upon passing.
Reporting for manuscript and clinical study report
Methods section: Include protocol registration number, full search strategy as appendix, selection criteria, data extraction process (forms), RoB tools, and statistical methods (effect measures, models, heterogeneity thresholds, sensitivity/subgroup plans), and software used. HYPERLINK \l "fn9" \h [9] HYPERLINK \l "fn1" \h [1]
Results: PRISMA flow diagram, summary tables (study characteristics; interventions and doses; comparator; outcomes), forest plots, RoB summary, GRADE evidence table, and biomarker-specific synthesis.
Supplementary: All extraction sheets (de-identified), analysis script (R/Stata), and raw pooled dataset (CSV) or a statement on data availability. Provide a short interpretation that avoids causal claims if included studies are observational/high risk. HYPERLINK \l "fn9" \h [9]
Data privacy, confidentiality, IP considerations and safeguards
Use only published aggregated data unless IPD is provided under a signed data-sharing agreement. For IPD requests: obtain IRB approval, data transfer agreements (DTA), and ensure de-identified datasets with controlled access. Maintain an author-contact log and permission records.
Intellectual property: Do not reproduce proprietary protocols or unpublished formulations; when patents or proprietary formulations are described, cite and summarize without replicating protected process details. In regulatory appendix, note any patents cited in included trials.
Storage & access: Store raw project files in institutionally approved encrypted repositories; restrict write access to core team; maintain an access log for audit.
Gating timeline, checkpoints, go/no-go decisions
Checkpoint 1 (After protocol registration): Proceed to search if protocol finalized and PROSPERO submission confirmed — go/no-go: go.
Checkpoint 2 (After search): Proceed to screening if search returns ≥20 unique clinical human studies or ≥5 human biomarker studies; otherwise, decide to broaden inclusion (preclinical, ex vivo) or stop. Go if threshold met; if not, discuss scope expansion.
Checkpoint 3 (After screening): Proceed to extraction if ≥3 clinical studies reporting a common primary outcome or ≥5 biomarker human studies; otherwise, pursue narrative synthesis only.
Checkpoint 4 (After risk-of-bias): Proceed to meta-analysis if at least 3 comparable low/moderate RoB studies exist; if not, do qualitative synthesis.
Final gate: Manuscript drafting proceeds irrespective of pooling; if pooled estimates are non-interpretable due to heterogeneity, produce structured narrative and highlight research gaps.
How to capture this in ethics/regulatory submissions
Attach protocol and PROSPERO registration to ethics/regulatory dossier; include data management plan, evidence of exemption (if applicable), and justification for use of published data only. If contacting authors for IPD, include IRB submission, consent templates (if contacting living participants), DTA templates, and data security plan. Include appendix listing data sources and any potential conflicts of interest or funding.
QC / acceptance thresholds summary table
Search breadth: ≥6 databases + 2 grey sources — pass/fail. (captured by librarian after search).
Screening concordance (kappa): ≥0.6 — pass; else retrain. (captured after first 200 abstracts).
Extraction discordance: ≤10% — pass; else re-extract sample. (captured during extraction).
Data availability for primary outcome: ≥50% of human studies — pass; else narrative. (captured at extraction end).
Meta-analysis heterogeneity: Pool if I² <75% and ≥3 comparable studies; else narrative. (captured at analysis).
RoB composition: ≤50% studies high RoB to proceed with pooled primary analysis; otherwise perform sensitivity analysis/exclude high RoB. (captured after RoB assessment).(Who reviews: methodologist, statistician, PI; when: at each milestone meeting.)
Reviewer guidance text to read verbatim (to minimize bias)
"You are asked to make independent judgments following the written protocol. Do not seek external opinions before recording your decision. Record reasons concisely and reference the exact protocol clause guiding your decision. If in doubt, mark 'uncertain' rather than forcing a binary choice. Timely flagging of conflicts to the adjudicator reduces downstream rework."
Low-resource / community settings execution example (concise)
Use Rayyan (free) for screening, Google Drive for shared PDFs, REDCap or Excel for extraction. Hold a 2-hour remote calibration session with recorded example screenings and one live adjudication. Upload extraction files weekly to central drive. The project coordinator in Pune synchronizes uploads and runs the R script on a pre-specified schedule for forest plots.
Manuscript-ready final section layout (what to include)
Title & abstract (structured), Introduction (gap + rationale), Methods (PICO, search, selection, extraction, RoB, analysis), Results (PRISMA, study table, RoB, main analyses, subgroup/biomarker syntheses), Discussion (limitations, heterogeneity, implications), Conclusion (limited, evidence-based), Data availability and protocol link, Acknowledgments, Funding/Conflicts, Appendices (search strings, extraction template, RoB, scripts). HYPERLINK \l "fn9" \h [9]
Example timeline (120 days) — checkpoints summarized
Days 0–7: Protocol, register PROSPERO.
Days 7–21: Search runs and dedup.
Days 22–35: Screening.
Days 36–56: Data extraction.
Days 57–70: Risk-of-bias assessment.
Days 71–98: Analysis and sensitivity/subgroup checks.
Days 99–120: Manuscript drafting and submission.
Final pragmatic notes and immediate next actions (what you can do now)
Immediate: finalize and approve protocol (I can draft a PROSPERO-ready protocol text), authorize search strings and databases (I can provide initial search blocks for chlorophyll/chlorophyllin, apigenin, quercetin, rutin, abscisic acid, and oral strip/film/lozenge terms), and set up Rayyan/Covidence and extraction templates. HYPERLINK \l "fn10" \h [10] HYPERLINK \l "fn11" \h [11]
If you want, I will:
(A) Draft the PROSPERO protocol text ready for submission (includes full PICO, inclusion/exclusion, and analysis plan) — or
(B) Produce the exact database search strings (PubMed, Embase, CENTRAL, Scopus) and an extraction template (REDCap/CSV) you can upload to your team.
Which should I prepare first?
⁂
Data Collection
Design a comprehensive literature search strategy for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip if relevant. Specify databases (PubMed, Scopus, Web of Science, Cochrane), Boolean logic and synonyms, language/date limits, and how grey literature / preprints will be handled. Provide one example search string.
Design a comprehensive literature search strategy for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip if relevant. Specify databases (PubMed, Scopus, Web of Science, Cochrane), Boolean logic and synonyms, language/date limits, and how grey literature / preprints will be handled. Provide one example search string. Turn the previous concept into an SOP-style procedure with step-by-step actions, responsible roles, minimum documentation required, and escalation triggers.
Design a comprehensive literature search strategy for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip if relevant. Specify databases (PubMed, Scopus, Web of Science, Cochrane), Boolean logic and synonyms, language/date limits, and how grey literature / preprints will be handled. Provide one example search string. Define quantitative quality indicators and thresholds that will prove this part of the study/review is working. Include how/when each metric is captured and who reviews it.
Design a comprehensive literature search strategy for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip if relevant. Specify databases (PubMed, Scopus, Web of Science, Cochrane), Boolean logic and synonyms, language/date limits, and how grey literature / preprints will be handled. Provide one example search string. Draft the patient/participant communication script or reviewer guidance text that should be read verbatim to maintain consistency and reduce bias.
Design a comprehensive literature search strategy for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip if relevant. Specify databases (PubMed, Scopus, Web of Science, Cochrane), Boolean logic and synonyms, language/date limits, and how grey literature / preprints will be handled. Provide one example search string. List foreseeable operational, ethical, or analytical failure modes in this part of the project and propose mitigation / contingency plans.
Design a comprehensive literature search strategy for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip if relevant. Specify databases (PubMed, Scopus, Web of Science, Cochrane), Boolean logic and synonyms, language/date limits, and how grey literature / preprints will be handled. Provide one example search string. Describe how this part of the project will be captured in regulatory or ethics submissions, including any appendices, audit trails, or notification requirements.
Design a comprehensive literature search strategy for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip if relevant. Specify databases (PubMed, Scopus, Web of Science, Cochrane), Boolean logic and synonyms, language/date limits, and how grey literature / preprints will be handled. Provide one example search string. Explain how digital tools, remote workflows, or decentralized methods will execute this part of the project in low-resource / community settings.
Design a comprehensive literature search strategy for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip if relevant. Specify databases (PubMed, Scopus, Web of Science, Cochrane), Boolean logic and synonyms, language/date limits, and how grey literature / preprints will be handled. Provide one example search string. Translate this part of the design into a training module outline for investigators, coordinators, community health workers, or evidence reviewers.
Design a comprehensive literature search strategy for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip if relevant. Specify databases (PubMed, Scopus, Web of Science, Cochrane), Boolean logic and synonyms, language/date limits, and how grey literature / preprints will be handled. Provide one example search string. Define how this part will be summarized in the final clinical study report or systematic review manuscript so it is publication-ready.
Design a comprehensive literature search strategy for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip if relevant. Specify databases (PubMed, Scopus, Web of Science, Cochrane), Boolean logic and synonyms, language/date limits, and how grey literature / preprints will be handled. Provide one example search string. Identify any data privacy, confidentiality, or IP considerations specific to this part, and describe safeguards.
Design a comprehensive literature search strategy for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip if relevant. Specify databases (PubMed, Scopus, Web of Science, Cochrane), Boolean logic and synonyms, language/date limits, and how grey literature / preprints will be handled. Provide one example search string. Propose timeline checkpoints, gating criteria, and go/no-go decisions specifically for this part before advancing to the next phase.
Below is a publication-ready search strategy for your review, designed to be broad enough for chlorophyll/chlorophyllin and flavonoid phytochemicals while still allowing oral-strip–specific filtering where relevant. I’ve also formatted it as an SOP-style workflow with roles, documentation, QC metrics, bias-reduction language, failure modes, and timeline gates. HYPERLINK \l "fn21" \h [21] HYPERLINK \l "fn22" \h [22]
Search scope
Population/problem: oral cancer, oral squamous cell carcinoma, and oral potentially malignant disorders.
Interventions/exposures: chlorophyll, chlorophyllin, apigenin, flavonoids, rutin, quercetin, abscisic acid, and standardized extracts containing these actives.
Delivery form filter: oral strip, buccal strip, oral film, buccal film, lozenge, mouth-dissolving film, mucoadhesive oral dosage forms, used as a secondary filter rather than a hard requirement.
Study types: clinical, translational, preclinical, and grey-literature records if they report relevant oral-cancer outcomes or biomarkers. HYPERLINK \l "fn23" \h [23] HYPERLINK \l "fn24" \h [24]
Databases to search
PubMed/MEDLINE: primary biomedical search.
Scopus: broad indexing for clinical, translational, and conference material.
Web of Science: citation tracking and multidisciplinary coverage.
Cochrane Library: trial registry and review cross-checking, plus CENTRAL if available.
Add a supplementary preprint search and targeted grey-literature sources because unpublished studies can reduce publication bias. HYPERLINK \l "fn25" \h [25] HYPERLINK \l "fn22" \h [22] HYPERLINK \l "fn26" \h [26]
Boolean logic
Use three concept blocks joined with AND:
Oral-cancer block.
Phytochemical block.
Oral-strip / local-delivery block, when you want formulation-specific retrieval.
Within each block, join synonyms with OR and use truncation where supported. Keep the formulation block optional in the first-pass search so you do not miss oral-cancer studies that mention the phytochemical without the strip term in the title/abstract. This approach matches systematic-review guidance that broad questions may require a larger evidence base, while narrower filters can be applied later during screening. HYPERLINK \l "fn27" \h [27] HYPERLINK \l "fn21" \h [21]
Synonyms to include
Oral cancer block: oral cancer, oral carcinoma, oral squamous cell carcinoma, OSCC, oral neoplasm*, oral malignan*, oral potentially malignant disorder*, leukoplakia, erythroplakia, oral dysplasia.
Chlorophyll block: chlorophyll, chlorophyllin, sodium copper chlorophyllin.
Apigenin/flavonoid block: apigenin, flavonoid*, flavone*, flavonoid-rich.
Quercetin/rutin block: quercetin, rutin, rutinose, glycoside.
Abscisic acid block: abscisic acid, ABA.
Oral-strip block: oral strip, buccal strip, oral film, buccal film, mucoadhesive film, dissolvable film, fast-dissolving film, lozenge, oral thin film. HYPERLINK \l "fn24" \h [24] HYPERLINK \l "fn25" \h [25]
Limits and filters
Language: include English by default; if the team has translation support, also screen abstracts in major languages and translate potentially eligible full texts on request.
Date range: no lower date limit initially; search from database inception to the search date, then update immediately before manuscript submission.
Study design filters: avoid narrow design filters at search stage unless the yield becomes unmanageable; apply design limits during screening instead.
Population filter: do not force human-only at first pass because preclinical and translational studies may help explain biomarker effects, but separate them in analysis. HYPERLINK \l "fn21" \h [21] HYPERLINK \l "fn23" \h [23]
Grey literature and preprints
Search trial registries, theses/dissertations, conference abstracts, institutional repositories, and relevant society proceedings.
Search preprint sources relevant to biomedicine and life sciences, then clearly label them as non–peer-reviewed during screening and synthesis.
Document each grey source separately in the PRISMA flow and methods, because PRISMA 2020 expects all databases, registers, websites, and other sources to be reported transparently. Use AACODS-style appraisal for grey literature. HYPERLINK \l "fn28" \h [28] HYPERLINK \l "fn29" \h [29] HYPERLINK \l "fn25" \h [25]
SOP-style procedure
Step 1: Build strategy
Action: Draft a master search string with three blocks and peer review it using a librarian or second reviewer.
Role: Information specialist leads; PI approves final scope.
Docs: search worksheet, synonym list, final approved strategy.
Escalation: if key term recall appears poor in pilot searches, expand synonyms and rerun.
Step 2: Run databases
Action: Execute the finalized search in PubMed, Scopus, Web of Science, and Cochrane.
Role: Information specialist.
Docs: exact search strings, date/time stamps, exported results.
Escalation: if one database produces unexpectedly few or no hits, review syntax and controlled vocabulary.
Step 3: Search grey sources
Action: Run registries, preprint servers, dissertations, conference sources, and citation chasing.
Role: Secondary reviewer or librarian.
Docs: grey-literature log, source URLs, hit counts.
Escalation: if a grey source yields many potentially eligible records, add source-specific screening notes.
Step 4: Deduplicate and archive
Action: Merge all exports in a reference manager and deduplicate.
Role: Data manager.
Docs: raw exports, dedup report, archived master library.
Escalation: if duplicate rate is unusually high or file integrity is poor, repeat import using a second method.
Step 5: Screen and update
Action: Title/abstract screening first, then full text; rerun an update search near submission.
Role: Two independent reviewers.
Docs: screening log, exclusion reasons, update-search log.
Escalation: unresolved disagreements go to adjudicator.
Example PubMed string
(("oral cancer"[tiab] OR "oral carcinoma"[tiab] OR "oral squamous cell carcinoma"[tiab] OR OSCC[tiab] OR "oral neoplasm*"[tiab] OR "oral malignan*"[tiab] OR leukoplakia[tiab] OR erythroplakia[tiab] OR "oral potentially malignant disorder*"[tiab] OR dysplasia[tiab])AND(chlorophyll[tiab] OR chlorophyllin[tiab] OR "sodium copper chlorophyllin"[tiab] OR apigenin[tiab] OR flavonoid*[tiab] OR quercetin[tiab] OR rutin[tiab] OR "abscisic acid"[tiab] OR ABA[tiab])AND("oral strip"[tiab] OR "buccal strip"[tiab] OR "oral film"[tiab] OR "buccal film"[tiab] OR mucoadhesive[tiab] OR lozenge[tiab] OR "fast dissolving"[tiab] OR "dissolving film"[tiab]))
Quality indicators
Database coverage: all four named databases searched and logged; pass if complete.
Search reproducibility: every query saved verbatim; pass if 100% archived.
Grey-source coverage: at least 5 distinct grey sources searched; pass if complete.
Yield sanity check: if zero hits in multiple databases, revise strategy before screening.
Peer-review of search: second-person review completed before final run; pass if documented.Metrics should be captured after each search wave and reviewed by the information specialist and PI. HYPERLINK \l "fn22" \h [22] HYPERLINK \l "fn25" \h [25]
Bias-reduction script
“Please apply the search strategy exactly as written. Do not add or remove terms without documenting the change. Record every database, date, and limit used. When in doubt, keep the search broad and handle specificity during screening rather than during retrieval.” HYPERLINK \l "fn22" \h [22] HYPERLINK \l "fn21" \h [21]
Failure modes and mitigations
Missed synonyms: pilot-search and expand terms.
Too many irrelevant hits: apply oral-strip filter in a second search wave or during screening.
Database syntax mismatch: translate the master string for each platform and test small batches.
Publication bias: include grey literature and preprints.
Language bias: use translation support for non-English full texts when potentially eligible. HYPERLINK \l "fn25" \h [25] HYPERLINK \l "fn23" \h [23]
Regulatory, ethics, and manuscript capture
In the protocol and ethics/regulatory appendices, include the complete search strategy, source list, dates searched, and a PRISMA-S style archive of the exact queries.
In the final manuscript, report databases, search dates, full strategies, grey-literature sources, and any update search. PRISMA 2020 expects transparent reporting of what was searched and how studies were identified. HYPERLINK \l "fn21" \h [21] HYPERLINK \l "fn22" \h [22]
Low-resource execution
Use free or low-cost tools: PubMed, Google Scholar for citation chasing, Rayyan for screening, Zotero for references, and shared spreadsheets for logs.
Store all search strings in a shared folder and assign one person to maintain the master search file so remote reviewers work from the same version.
If internet access is intermittent, export database results as RIS/CSV and screen offline in batches. HYPERLINK \l "fn26" \h [26] HYPERLINK \l "fn25" \h [25]
Training outline
Module 1: Review question and concept blocks.
Module 2: Building Boolean strings and synonyms.
Module 3: Database-specific translation.
Module 4: Grey literature and preprints.
Module 5: Documentation, PRISMA flow, and archiving.
Module 6: Update searches and final audit. HYPERLINK \l "fn22" \h [22] HYPERLINK \l "fn21" \h [21]
Timeline and go/no-go
Day 1–3: finalize terms and pilot search.
Day 4–7: run all databases and grey sources.
Day 8: verify yield and deduplicate.
Go: if searches are reproducible and at least two databases plus one grey source are complete.
No-go: if the strategy cannot retrieve known sentinel papers, or if the syntax is not reproducible across platforms. HYPERLINK \l "fn24" \h [24] HYPERLINK \l "fn22" \h [22]
⁂
Bias & Risk
Describe study screening for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Define inclusion/exclusion criteria, dual-review screening process, conflict resolution, and how PRISMA flow (identified / screened / excluded / included) will be documented. Mention tools such as Covidence, Rayyan, or Excel.
Describe study screening for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Define inclusion/exclusion criteria, dual-review screening process, conflict resolution, and how PRISMA flow (identified / screened / excluded / included) will be documented. Mention tools such as Covidence, Rayyan, or Excel. Turn the previous concept into an SOP-style procedure with step-by-step actions, responsible roles, minimum documentation required, and escalation triggers.
Describe study screening for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Define inclusion/exclusion criteria, dual-review screening process, conflict resolution, and how PRISMA flow (identified / screened / excluded / included) will be documented. Mention tools such as Covidence, Rayyan, or Excel. Define quantitative quality indicators and thresholds that will prove this part of the study/review is working. Include how/when each metric is captured and who reviews it.
Describe study screening for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Define inclusion/exclusion criteria, dual-review screening process, conflict resolution, and how PRISMA flow (identified / screened / excluded / included) will be documented. Mention tools such as Covidence, Rayyan, or Excel. Draft the patient/participant communication script or reviewer guidance text that should be read verbatim to maintain consistency and reduce bias.
Describe study screening for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Define inclusion/exclusion criteria, dual-review screening process, conflict resolution, and how PRISMA flow (identified / screened / excluded / included) will be documented. Mention tools such as Covidence, Rayyan, or Excel. List foreseeable operational, ethical, or analytical failure modes in this part of the project and propose mitigation / contingency plans.
Describe study screening for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Define inclusion/exclusion criteria, dual-review screening process, conflict resolution, and how PRISMA flow (identified / screened / excluded / included) will be documented. Mention tools such as Covidence, Rayyan, or Excel. Describe how this part of the project will be captured in regulatory or ethics submissions, including any appendices, audit trails, or notification requirements.
Describe study screening for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Define inclusion/exclusion criteria, dual-review screening process, conflict resolution, and how PRISMA flow (identified / screened / excluded / included) will be documented. Mention tools such as Covidence, Rayyan, or Excel. Explain how digital tools, remote workflows, or decentralized methods will execute this part of the project in low-resource / community settings.
Describe study screening for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Define inclusion/exclusion criteria, dual-review screening process, conflict resolution, and how PRISMA flow (identified / screened / excluded / included) will be documented. Mention tools such as Covidence, Rayyan, or Excel. Translate this part of the design into a training module outline for investigators, coordinators, community health workers, or evidence reviewers.
Describe study screening for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Define inclusion/exclusion criteria, dual-review screening process, conflict resolution, and how PRISMA flow (identified / screened / excluded / included) will be documented. Mention tools such as Covidence, Rayyan, or Excel. Define how this part will be summarized in the final clinical study report or systematic review manuscript so it is publication-ready.
Describe study screening for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Define inclusion/exclusion criteria, dual-review screening process, conflict resolution, and how PRISMA flow (identified / screened / excluded / included) will be documented. Mention tools such as Covidence, Rayyan, or Excel. Identify any data privacy, confidentiality, or IP considerations specific to this part, and describe safeguards.
Describe study screening for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Define inclusion/exclusion criteria, dual-review screening process, conflict resolution, and how PRISMA flow (identified / screened / excluded / included) will be documented. Mention tools such as Covidence, Rayyan, or Excel. Propose timeline checkpoints, gating criteria, and go/no-go decisions specifically for this part before advancing to the next phase.
Create a standardized data extraction table for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. List study ID, year, country, design, sample size, intervention/exposure details, comparator, outcome metrics, follow-up duration, and key numerical results. Explain how missing/unclear data will be handled.
Below is a screening SOP you can drop into the methods section and operational checklist for this oral-cancer phytochemical review. It covers eligibility criteria, dual screening, conflict resolution, PRISMA documentation, QC metrics, and the standardized extraction table. HYPERLINK \l "fn37" \h [37] HYPERLINK \l "fn38" \h [38]
Screening criteria
Include studies in oral cancer, OSCC, or OPMDs that evaluate chlorophyll/chlorophyllin, apigenin/flavonoids, quercetin/rutin, or abscisic acid, including oral-strip, buccal-film, lozenge, or other local oral delivery forms. Include human clinical trials, observational studies, and translational studies if they report eligible outcomes or biomarker data. HYPERLINK \l "fn39" \h [39] HYPERLINK \l "fn40" \h [40]
Exclude papers that are not original research, do not involve oral-cancer–relevant populations or models, do not evaluate the target actives, are purely formulation-only with no biological outcome, or are outside scope after full-text review. Record reasons for every full-text exclusion. HYPERLINK \l "fn41" \h [41] HYPERLINK \l "fn42" \h [42]
Language/date: keep the review broad; do not exclude by year at screening unless pre-specified by the protocol, and avoid language restriction unless translation is impossible. Language limits can introduce bias, so any language exclusion must be documented. HYPERLINK \l "fn40" \h [40]
Screening workflow
Title/abstract screening comes first, then full-text screening, and both are done by two independent reviewers working blindly to each other’s decisions. This is the standard approach to reduce selection bias. HYPERLINK \l "fn43" \h [43] HYPERLINK \l "fn38" \h [38] HYPERLINK \l "fn44" \h [44]
If either reviewer marks a record as “include” or “uncertain,” it advances to full text; screeners should be permissive at the title/abstract stage to avoid false negatives. HYPERLINK \l "fn43" \h [43] HYPERLINK \l "fn39" \h [39]
Full-text screening applies the protocol eligibility criteria more strictly, and all exclusions must have a specific reason coded in the screening tool. HYPERLINK \l "fn42" \h [42] HYPERLINK \l "fn39" \h [39]
Conflict resolution
Disagreements are resolved first by discussion between the two screeners, then by a third senior reviewer if needed. If the full text is unavailable, the record should be logged as “not retrievable” after reasonable attempts. HYPERLINK \l "fn38" \h [38] HYPERLINK \l "fn42" \h [42]
Use a predefined arbitration rule: when disagreement persists after one discussion round, escalate to the adjudicator within 48 hours. HYPERLINK \l "fn39" \h [39] HYPERLINK \l "fn40" \h [40]
If screening agreement is poor during pilot testing, retrain the team and re-screen a calibration sample before continuing. HYPERLINK \l "fn40" \h [40]
PRISMA flow documentation
Use the PRISMA 2020 flow diagram to document records identified, removed as duplicates, screened, excluded, full-text assessed, full-text excluded with reasons, and studies included. The PRISMA diagram is specifically intended to show the flow of information through the review phases. HYPERLINK \l "fn45" \h [45] HYPERLINK \l "fn37" \h [37]
Keep separate counts for database searches, registers, grey literature, and preprints when applicable, because PRISMA 2020 supports reporting sources separately. HYPERLINK \l "fn46" \h [46] HYPERLINK \l "fn37" \h [37]
Document counts in a master screening log and export them into the PRISMA figure at the end of full-text screening and again at the final update search. HYPERLINK \l "fn47" \h [47] HYPERLINK \l "fn41" \h [41]
Tools
Covidence is ideal for blinded dual screening, conflict management, and PRISMA-style exports. HYPERLINK \l "fn38" \h [38] HYPERLINK \l "fn43" \h [43]
Rayyan is a good lower-cost alternative for blinded screening and tagging reasons. HYPERLINK \l "fn41" \h [41]
Excel or Google Sheets can be used as a backup audit log for counts, reasons, and reviewer initials, especially in low-resource settings. HYPERLINK \l "fn41" \h [41]
SOP procedure
Step 1: Prepare criteria
Action: Finalize inclusion/exclusion criteria in a coded screening sheet with examples.
Role: Lead investigator and methodologist.
Docs: protocol section, decision rules, calibration examples.
Escalation: if criteria are interpreted inconsistently in pilot cases, revise definitions before live screening.
Step 2: Pilot calibration
Action: Screen a small shared sample and compare decisions.
Role: Two reviewers plus adjudicator.
Docs: pilot log, disagreement notes, revised rules.
Escalation: if agreement is low, repeat training and re-pilot.
Step 3: Title/abstract screening
Action: Screen all records independently in Covidence/Rayyan.
Role: Two reviewers.
Docs: screening decisions, reason tags for exclusions only if your tool captures them at this stage.
Escalation: any uncertain record goes to full text.
Step 4: Full-text retrieval
Action: Retrieve PDFs for all potentially eligible studies.
Role: Reviewers or librarian.
Docs: retrieval log, not-retrieved list.
Escalation: if more than a small fraction cannot be obtained, trigger interlibrary loan or author contact.
Step 5: Full-text screening
Action: Apply eligibility criteria line by line and assign one exclusion reason if excluded.
Role: Two reviewers, with adjudicator for conflicts.
Docs: full-text forms, exclusion reason codes, adjudication notes.
Escalation: unresolved conflicts after discussion go to third reviewer.
Step 6: Final PRISMA counts
Action: Export counts and create the PRISMA flow diagram.
Role: Data manager and PI.
Docs: final counts sheet, diagram file, audit trail.
Escalation: if counts do not reconcile with the reference manager or screening tool, reconcile line by line before manuscript drafting.
Quality indicators
Dual-screen coverage: 100% of records screened independently by two reviewers; checked after every batch by the project manager.
Calibration agreement: target Cohen’s kappa or percent agreement above a pre-set threshold after pilot screening; reviewed by the methodologist before live screening.
Conflict rate: monitor percentage of disagreements; unusually high rates trigger retraining.
Retrieval success: target near-complete full-text retrieval; missing texts should be tracked and escalated weekly.
Reason coding completeness: 100% of full-text exclusions must have a reason; reviewed by the PI at the end of screening.These metrics should be captured weekly during screening and reviewed in team meetings. HYPERLINK \l "fn48" \h [48] HYPERLINK \l "fn39" \h [39]
Verbatim reviewer guidance
“Screen each citation independently using only the protocol criteria. If the title or abstract is unclear, move it forward rather than excluding it. Do not discuss decisions with the other screener until both votes are recorded. At full text, record one clear exclusion reason if the paper does not qualify.” HYPERLINK \l "fn42" \h [42] HYPERLINK \l "fn39" \h [39]
Failure modes and mitigations
Missed eligible studies: keep title/abstract screening permissive, then verify at full text. HYPERLINK \l "fn43" \h [43]
Reviewer drift: run calibration samples every few hundred records. HYPERLINK \l "fn40" \h [40]
Poor full-text access: use librarian support and author contact; track unretrieved items separately. HYPERLINK \l "fn41" \h [41]
Ambiguous multi-report studies: group by study, not by paper, before final inclusion. HYPERLINK \l "fn37" \h [37]
Over-restrictive oral-strip filter: treat strip/film terms as a secondary tag, not a hard first-pass exclusion.
Ethics and regulatory capture
Screening usually uses published material only, so it is typically exempt from human-subject consent; nevertheless, the protocol, decision rules, and PRISMA flow should be attached to the ethics or institutional review file as appendices. HYPERLINK \l "fn49" \h [49] HYPERLINK \l "fn37" \h [37]
If you contact authors or handle unpublished data, keep a dated audit trail of outreach and responses, and store only de-identified files.
Include the final PRISMA diagram, full exclusion-reason table, and screening SOP in the manuscript supplement for transparency. HYPERLINK \l "fn50" \h [50] HYPERLINK \l "fn45" \h [45]
Low-resource execution
Use Rayyan or Excel if Covidence is unavailable.
Work in batches with a shared spreadsheet for counts and conflict notes.
If internet access is intermittent, export citations to CSV/RIS and screen offline, then sync decisions later. HYPERLINK \l "fn38" \h [38] HYPERLINK \l "fn41" \h [41]
Training module outline
Module 1: eligibility criteria and examples.
Module 2: title/abstract screening practice.
Module 3: full-text screening and exclusion reasons.
Module 4: conflict resolution and arbitration.
Module 5: PRISMA flow documentation and audit trail.
Module 6: tool practice in Covidence, Rayyan, or Excel. HYPERLINK \l "fn39" \h [39] HYPERLINK \l "fn38" \h [38]
Manuscript-ready summary
In the methods, report that two reviewers independently screened all records in blinded fashion, conflicts were resolved by consensus/third reviewer, exclusion reasons were recorded at full text, and study selection was reported with a PRISMA 2020 flow diagram. HYPERLINK \l "fn45" \h [45] HYPERLINK \l "fn37" \h [37]
In the results, report counts for identified, deduplicated, screened, full-text assessed, excluded with reasons, and included studies.
In supplementary files, include the screening decision tree, exclusion codes, and a reconciliation log.
Standard extraction table
Study ID
Year
Country
Design
Sample size
Intervention / exposure details
Comparator
Outcome metrics
Follow-up
Key numerical results
Missing data handling
Example_01
2024
India
RCT
48
Chlorophyllin oral strip, dose/frequency/duration
Placebo strip
lesion size, pain score, biomarker panel
8 weeks
mean change, RR, CI, p-value
mark as “NR”; contact author; extract from figure if needed
Example_02
2023
Japan
Pilot clinical
22
Quercetin/rutin mucoadhesive film
Usual care
dysplasia grade, tolerability
12 weeks
median change, SD/IQR, AE rate
convert units if possible; otherwise narrate
Example_03
2022
Brazil
Observational
61
Apigenin/flavonoid exposure
Unexposed
OSCC progression, survival
1 year
adjusted HR/OR, CI
retain adjusted estimate only
Example_04
2021
China
Preclinical/ex vivo
12
Abscisic acid oral-mucosa exposure
Vehicle
apoptosis, MMP-9, NF-κB
acute
fold-change, mean ± SD
flag separately from human studies

Missing/unclear data: first contact authors, then use reported graphs/tables, then impute only if prespecified and defensible; never invent values. If a study remains unusable for quantitative synthesis, keep it in narrative synthesis and document the limitation. HYPERLINK \l "fn39" \h [39] HYPERLINK \l "fn40" \h [40]
⁂
Ethics & Regulatory
Create a standardized data extraction table for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. List study ID, year, country, design, sample size, intervention/exposure details, comparator, outcome metrics, follow-up duration, and key numerical results. Explain how missing/unclear data will be handled. Turn the previous concept into an SOP-style procedure with step-by-step actions, responsible roles, minimum documentation required, and escalation triggers.
Create a standardized data extraction table for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. List study ID, year, country, design, sample size, intervention/exposure details, comparator, outcome metrics, follow-up duration, and key numerical results. Explain how missing/unclear data will be handled. Define quantitative quality indicators and thresholds that will prove this part of the study/review is working. Include how/when each metric is captured and who reviews it.
Create a standardized data extraction table for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. List study ID, year, country, design, sample size, intervention/exposure details, comparator, outcome metrics, follow-up duration, and key numerical results. Explain how missing/unclear data will be handled. Draft the patient/participant communication script or reviewer guidance text that should be read verbatim to maintain consistency and reduce bias.
Create a standardized data extraction table for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. List study ID, year, country, design, sample size, intervention/exposure details, comparator, outcome metrics, follow-up duration, and key numerical results. Explain how missing/unclear data will be handled. List foreseeable operational, ethical, or analytical failure modes in this part of the project and propose mitigation / contingency plans.
Create a standardized data extraction table for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. List study ID, year, country, design, sample size, intervention/exposure details, comparator, outcome metrics, follow-up duration, and key numerical results. Explain how missing/unclear data will be handled. Describe how this part of the project will be captured in regulatory or ethics submissions, including any appendices, audit trails, or notification requirements.
Create a standardized data extraction table for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. List study ID, year, country, design, sample size, intervention/exposure details, comparator, outcome metrics, follow-up duration, and key numerical results. Explain how missing/unclear data will be handled. Explain how digital tools, remote workflows, or decentralized methods will execute this part of the project in low-resource / community settings.
Create a standardized data extraction table for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. List study ID, year, country, design, sample size, intervention/exposure details, comparator, outcome metrics, follow-up duration, and key numerical results. Explain how missing/unclear data will be handled. Translate this part of the design into a training module outline for investigators, coordinators, community health workers, or evidence reviewers.
Create a standardized data extraction table for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. List study ID, year, country, design, sample size, intervention/exposure details, comparator, outcome metrics, follow-up duration, and key numerical results. Explain how missing/unclear data will be handled. Define how this part will be summarized in the final clinical study report or systematic review manuscript so it is publication-ready.
Create a standardized data extraction table for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. List study ID, year, country, design, sample size, intervention/exposure details, comparator, outcome metrics, follow-up duration, and key numerical results. Explain how missing/unclear data will be handled. Identify any data privacy, confidentiality, or IP considerations specific to this part, and describe safeguards.
Create a standardized data extraction table for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. List study ID, year, country, design, sample size, intervention/exposure details, comparator, outcome metrics, follow-up duration, and key numerical results. Explain how missing/unclear data will be handled. Propose timeline checkpoints, gating criteria, and go/no-go decisions specifically for this part before advancing to the next phase.
Define the risk-of-bias / quality assessment method for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Indicate which tool applies (Cochrane RoB 2, ROBINS-I, Newcastle–Ottawa, JBI). Explain reviewer calibration, disagreement resolution, and how bias profiles will be summarized visually.
Below is a standardized data extraction and risk-of-bias workflow for your oral-cancer phytochemical review. I’ve formatted it as a practical SOP you can use in Excel, REDCap, Covidence exports, or Rayyan notes, with fields that are publication-ready and easy to pool later. HYPERLINK \l "fn69" \h [69] HYPERLINK \l "fn70" \h [70]
Extraction table
Use one row per study, and if a study has multiple relevant arms, keep a linked arm-level sheet.
Study ID
Year
Country
Design
Sample size
Intervention / exposure details
Comparator
Outcome metrics
Follow-up duration
Key numerical results
Missing data flag
OC-001
2024
India
RCT
48
Chlorophyllin oral strip, dose, frequency, excipients, duration
Placebo strip
lesion size, pain score, biomarker panel
8 weeks
mean change, SD, RR/OR, CI, p-value
NR / unclear / imputed
OC-002
2023
Japan
Pilot clinical
22
Quercetin-rutin mucoadhesive film, standardized dose
Usual care
dysplasia grade, tolerability, QoL
12 weeks
median change, IQR, AE rate
NR / unclear / imputed
OC-003
2022
Brazil
Observational cohort
61
Apigenin/flavonoid exposure, route, dose if reported
Unexposed
progression, recurrence, survival
1 year
adjusted HR/OR with CI
NR / unclear / imputed
OC-004
2021
China
Preclinical / ex vivo
12
Abscisic acid oral-mucosa exposure, concentration
Vehicle
apoptosis, NF-κB, MMP-9
acute / 24–72 h
fold-change, mean ± SD
NR / unclear / imputed

The PRISMA 2020 framework expects transparent reporting of study characteristics, sources, and results, and its flow diagram is meant to show how records move from identification to inclusion. HYPERLINK \l "fn70" \h [70] HYPERLINK \l "fn69" \h [69]
Data fields
Capture the following for each study:
Study ID: unique code, e.g., OC-001.
Bibliographic info: authors, year, journal, DOI/PMID.
Country and setting: single-center vs multicenter.
Design: RCT, nonrandomized trial, cohort, case-control, pilot, ex vivo, animal, or mixed.
Population: oral cancer, OSCC, OPMD subtype, age, sex, baseline severity.
Intervention/exposure: compound name, formulation, route, dose, schedule, duration, standardization marker.
Comparator: placebo, vehicle, blank strip, standard care, or no exposure.
Outcomes: primary and secondary endpoints, assay method, timepoint.
Effect data: n, mean, SD, median/IQR, RR, OR, HR, CI, p-values.
Follow-up: exact duration and visit schedule.
Notes: funding, conflicts, protocol registration, deviations.
Missing data handling
If a study reports an outcome without numerical detail, flag it as NR and try to extract from tables, text, or figures first.
If the value is only in graphs, digitize it using a prespecified method and record that it was digitized.
If a statistic is missing but derivable from another metric, convert only when the conversion is standard and defensible.
If essential data remain unclear, contact the corresponding author and log the request date, response date, and outcome.
If the study still cannot be used quantitatively, keep it in narrative synthesis and mark it “not poolable.” HYPERLINK \l "fn69" \h [69] HYPERLINK \l "fn70" \h [70]
SOP procedure
Step 1: Prepare form
Action: Build a locked extraction template in Excel, REDCap, or Covidence export format.
Role: Data manager and statistician.
Docs: versioned template, data dictionary, variable definitions.
Escalation: if key variables are ambiguous, revise definitions before extraction begins.
Step 2: Train extractors
Action: Run a pilot on 2–3 studies and compare extracted fields.
Role: Lead reviewer, two extractors.
Docs: pilot extraction, discrepancy log, revised guidance.
Escalation: if discrepancies are frequent, re-train before live extraction.
Step 3: Dual extraction
Action: Two reviewers independently extract each study.
Role: Extractor A, Extractor B.
Docs: independent copies, time stamps, source PDFs.
Escalation: differences above threshold trigger consensus review.
Step 4: Reconcile and verify
Action: Compare fields and resolve disagreements line by line.
Role: Senior reviewer or statistician as adjudicator.
Docs: reconciliation log, final master dataset.
Escalation: unresolved numeric discrepancies go to PI.
Step 5: Freeze dataset
Action: Lock the clean dataset and generate analysis-ready CSV.
Role: Data manager.
Docs: freeze notice, file checksum, version history.
Escalation: any post-freeze changes require a change-control entry.
Quality indicators
Template completeness: 100% of pre-specified fields present in the form.
Extraction agreement: target ≥90% field-level agreement in pilot; reviewed after the pilot and after every 10 studies.
Numeric verification: 100% of effect-size fields cross-checked by a second reviewer; reviewed weekly by the statistician.
Missing-data rate: proportion of critical fields marked NR should stay below a prespecified threshold; reviewed at the end of each batch.
Author-contact yield: proportion of queried authors who provide clarifications; reviewed monthly by the PI.If agreement falls below threshold, pause extraction and retrain. HYPERLINK \l "fn70" \h [70] HYPERLINK \l "fn69" \h [69]
Reviewer guidance text
“Extract only what the paper explicitly reports or what can be converted using standard, documented methods. Do not guess missing values. If the value is unclear, flag it, add a source note, and send it for adjudication. Keep one record per study, and link multiple reports of the same study together before entering effect estimates.” HYPERLINK \l "fn69" \h [69]
Failure modes and mitigations
Duplicate study records: link reports by author, setting, and sample before extraction.
Mixed reporting units: standardize units in the data dictionary and convert systematically.
Over-extraction of irrelevant details: limit mandatory fields to prespecified variables only.
Digitization errors: verify graph-extracted values against reported ranges whenever possible.
Author nonresponse: preserve a narrative entry and use the available data transparently. HYPERLINK \l "fn70" \h [70] HYPERLINK \l "fn69" \h [69]
Risk of bias / quality assessment
Use the tool that matches the study design:
RoB 2 for randomized trials.
ROBINS-I for nonrandomized intervention studies.
Newcastle–Ottawa Scale for cohort and case-control studies if you need a simpler observational tool.
JBI checklists for selected nonrandomized or case-series style evidence.
Apply two independent reviewers, use a calibration set first, and resolve disagreements by discussion followed by third-party adjudication if needed. Summarize bias visually with domain-level traffic-light plots for RoB 2, a ROBINS-I heatmap or traffic-light matrix, and a study-level summary table plus an overall weighted judgment. PRISMA 2020 recommends transparent reporting of the methods and results used to assess risk of bias and synthesize the evidence. HYPERLINK \l "fn69" \h [69] HYPERLINK \l "fn70" \h [70]
SOP for bias assessment
Step 1: Select tool
Action: Assign RoB 2, ROBINS-I, NOS, or JBI based on design.
Role: Methodologist.
Docs: decision matrix by design.
Escalation: borderline designs reviewed by PI.
Step 2: Calibrate
Action: Score 1–2 sample studies together.
Role: Two assessors.
Docs: calibration sheet, examples, clarifications.
Escalation: if ratings diverge materially, retrain.
Step 3: Independent scoring
Action: Score all domains separately and independently.
Role: Assessor A and B.
Docs: completed forms, notes, quotes.
Escalation: disagreements go to adjudicator.
Step 4: Visual summary
Action: Produce traffic-light/heatmap summary and study-level table.
Role: Statistician and methodologist.
Docs: visual output, legend, rationale notes.
Escalation: if many studies are high risk, do sensitivity analyses.
Regulatory, privacy, and IP notes
This step usually uses published information only, so it is generally low risk from a privacy standpoint.
Store PDFs and extracted data in encrypted, access-controlled folders.
If any unpublished patient-level data are requested, use de-identified files and maintain a data-transfer log.
Keep an audit trail of all extraction changes because the PRISMA methods and results should be reproducible and updateable. HYPERLINK \l "fn70" \h [70] HYPERLINK \l "fn69" \h [69]
Publication-ready summary
In the manuscript, describe the extraction process as follows: “Two reviewers independently extracted prespecified study characteristics, intervention details, comparator data, outcome metrics, follow-up, and numerical results using a standardized form. Discrepancies were resolved by consensus and adjudication. Risk of bias was assessed using design-appropriate tools, and the final dataset was verified and locked before analysis.” HYPERLINK \l "fn69" \h [69]
Timeline and go/no-go
Day 1–3: finalize extraction form and data dictionary.
Day 4–7: pilot and calibrate.
Day 8–21: dual extraction in batches.
Day 22: reconcile and freeze.
Go: if pilot agreement is acceptable and all critical fields are defined.
No-go: if more than a small share of studies cannot supply extractable numeric outcomes or if extractors disagree repeatedly on core fields. HYPERLINK \l "fn69" \h [69]
⁂
Statistical Analysis
Define the risk-of-bias / quality assessment method for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Indicate which tool applies (Cochrane RoB 2, ROBINS-I, Newcastle–Ottawa, JBI). Explain reviewer calibration, disagreement resolution, and how bias profiles will be summarized visually. Turn the previous concept into an SOP-style procedure with step-by-step actions, responsible roles, minimum documentation required, and escalation triggers.
Define the risk-of-bias / quality assessment method for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Indicate which tool applies (Cochrane RoB 2, ROBINS-I, Newcastle–Ottawa, JBI). Explain reviewer calibration, disagreement resolution, and how bias profiles will be summarized visually. Define quantitative quality indicators and thresholds that will prove this part of the study/review is working. Include how/when each metric is captured and who reviews it.
Define the risk-of-bias / quality assessment method for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Indicate which tool applies (Cochrane RoB 2, ROBINS-I, Newcastle–Ottawa, JBI). Explain reviewer calibration, disagreement resolution, and how bias profiles will be summarized visually. Draft the patient/participant communication script or reviewer guidance text that should be read verbatim to maintain consistency and reduce bias.
Define the risk-of-bias / quality assessment method for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Indicate which tool applies (Cochrane RoB 2, ROBINS-I, Newcastle–Ottawa, JBI). Explain reviewer calibration, disagreement resolution, and how bias profiles will be summarized visually. List foreseeable operational, ethical, or analytical failure modes in this part of the project and propose mitigation / contingency plans.
Define the risk-of-bias / quality assessment method for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Indicate which tool applies (Cochrane RoB 2, ROBINS-I, Newcastle–Ottawa, JBI). Explain reviewer calibration, disagreement resolution, and how bias profiles will be summarized visually. Describe how this part of the project will be captured in regulatory or ethics submissions, including any appendices, audit trails, or notification requirements.
Define the risk-of-bias / quality assessment method for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Indicate which tool applies (Cochrane RoB 2, ROBINS-I, Newcastle–Ottawa, JBI). Explain reviewer calibration, disagreement resolution, and how bias profiles will be summarized visually. Explain how digital tools, remote workflows, or decentralized methods will execute this part of the project in low-resource / community settings.
Define the risk-of-bias / quality assessment method for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Indicate which tool applies (Cochrane RoB 2, ROBINS-I, Newcastle–Ottawa, JBI). Explain reviewer calibration, disagreement resolution, and how bias profiles will be summarized visually. Translate this part of the design into a training module outline for investigators, coordinators, community health workers, or evidence reviewers.
Define the risk-of-bias / quality assessment method for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Indicate which tool applies (Cochrane RoB 2, ROBINS-I, Newcastle–Ottawa, JBI). Explain reviewer calibration, disagreement resolution, and how bias profiles will be summarized visually. Define how this part will be summarized in the final clinical study report or systematic review manuscript so it is publication-ready.
Define the risk-of-bias / quality assessment method for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Indicate which tool applies (Cochrane RoB 2, ROBINS-I, Newcastle–Ottawa, JBI). Explain reviewer calibration, disagreement resolution, and how bias profiles will be summarized visually. Identify any data privacy, confidentiality, or IP considerations specific to this part, and describe safeguards.
Define the risk-of-bias / quality assessment method for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Indicate which tool applies (Cochrane RoB 2, ROBINS-I, Newcastle–Ottawa, JBI). Explain reviewer calibration, disagreement resolution, and how bias profiles will be summarized visually. Propose timeline checkpoints, gating criteria, and go/no-go decisions specifically for this part before advancing to the next phase.
Plan the quantitative synthesis for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Specify fixed-effect vs random-effects model (and why), pooled effect size calculation, heterogeneity stats (I², τ²), subgroup analyses, sensitivity analyses, and which forest / funnel plots you expect to generate.
Use a design-specific risk-of-bias plan: RoB 2 for randomized trials, ROBINS-I for nonrandomized intervention studies, Newcastle–Ottawa Scale for cohort/case-control studies if you need a simpler observational tool, and JBI checklists for case series, cross-sectional, or other descriptive designs. HYPERLINK \l "fn71" \h [71] HYPERLINK \l "fn72" \h [72] HYPERLINK \l "fn73" \h [73]
Tool selection
RoB 2: use for individually randomized or cluster/crossover randomized trials; it is Cochrane’s recommended tool for randomized trials and yields Low / Some concerns / High judgments across fixed domains. HYPERLINK \l "fn74" \h [74] HYPERLINK \l "fn71" \h [71]
ROBINS-I: use for nonrandomized intervention studies where confounding, selection, and deviation from intended intervention are major concerns. HYPERLINK \l "fn72" \h [72] HYPERLINK \l "fn75" \h [75]
Newcastle–Ottawa Scale (NOS): use for cohort or case-control studies when you want a compact observational appraisal, especially for prevalence of bias signals rather than full causal inference. HYPERLINK \l "fn73" \h [73] HYPERLINK \l "fn76" \h [76]
JBI: use for case series or other descriptive evidence where NOS/ROBINS-I are not a good fit. HYPERLINK \l "fn76" \h [76]
Visual summary
Summarize risk of bias with traffic-light plots for RoB 2, domain-by-domain heatmaps or traffic-light matrices for ROBINS-I, and study-level summary tables for NOS/JBI.
Include an overall figure showing the distribution of low/moderate/high risk across studies and a domain-specific bar chart for the most common bias sources.
In the manuscript, present a concise “bias profile” figure plus a table that lists the final judgment and one-line rationale per study. HYPERLINK \l "fn77" \h [77] HYPERLINK \l "fn71" \h [71]
SOP procedure
Step 1: Assign tool
Action: Classify each included study by design and assign the matching tool.
Role: Methodologist.
Docs: design classification sheet, tool assignment log.
Escalation: ambiguous designs go to PI for final assignment.
Step 2: Calibrate reviewers
Action: Score 2–3 sample studies together and discuss domain interpretations before independent scoring.
Role: Two assessors and methodologist.
Docs: calibration notes, scored examples, clarified rules.
Escalation: if early disagreement is frequent, pause and retrain.
Step 3: Independent assessment
Action: Each reviewer scores all domains independently using the chosen tool.
Role: Assessor A and Assessor B.
Docs: completed forms, quoted support text, judgment rationale.
Escalation: any “unclear” or “conflict” judgment is flagged.
Step 4: Resolve disagreements
Action: Compare judgments, discuss each discrepant domain, and document the final consensus; if needed, use a third reviewer.
Role: Two assessors, adjudicator.
Docs: discrepancy log, final consensus record.
Escalation: unresolved disagreements after one round go to adjudicator within 48 hours.
Step 5: Summarize visually
Action: Convert final judgments into figures and summary tables.
Role: Statistician / data manager.
Docs: figure files, legend, study-level table, audit trail.
Escalation: if many studies are high risk, pre-specify sensitivity analyses and downgrade certainty.
Quality indicators
Calibration agreement: target substantial agreement after pilot scoring; captured after the first 2–3 studies and reviewed by the methodologist.
Domain completeness: 100% of prespecified domains scored for each study; checked after every batch.
Disagreement rate: keep unresolved disagreements low; any repeated domain conflicts trigger retraining.
Rationale completeness: every final judgment should have a written evidence note; reviewed by the PI at batch close.
Timeliness: complete RoB assessment within the planned window for each batch; tracked weekly by the project manager.If calibration is weak or many studies remain “unclear,” stop and retrain before proceeding to synthesis. HYPERLINK \l "fn78" \h [78] HYPERLINK \l "fn71" \h [71]
Verbatim reviewer guidance
“Score only what is supported by the study report. Do not infer unreported methods or outcomes. When a domain is unclear, use the tool’s ‘some concerns’ or equivalent intermediate option rather than forcing a favorable judgment. Record the exact passage or table supporting each decision, and escalate unresolved conflicts for adjudication.” HYPERLINK \l "fn71" \h [71] HYPERLINK \l "fn72" \h [72]
Failure modes and mitigations
Wrong tool chosen for design: use the study design decision tree before scoring.
Over-interpretation of sparse reporting: stick to reported information only.
Long assessment time for ROBINS-I: reserve it for studies where causal interpretation matters; use NOS/JBI where appropriate. HYPERLINK \l "fn78" \h [78]
Reviewer drift: re-calibrate after every batch of studies.
Inconsistent labeling of “high risk” vs “some concerns”: keep a one-page decision rule sheet beside the form. HYPERLINK \l "fn71" \h [71]
Documentation and audit trail
Keep the design-classification sheet, calibration notes, all independent RoB forms, adjudication logs, and final summary plots in a versioned folder.
Include an appendix in the manuscript with the tool names, domain definitions, and rationale for each study-level judgment.
If the review is registered, note the planned tool selection in the protocol and log any changes as amendments. HYPERLINK \l "fn79" \h [79] HYPERLINK \l "fn77" \h [77]
Low-resource execution
Use Excel if Covidence or dedicated RoB software is unavailable; add dropdowns for domains and free-text rationale boxes.
Work remotely by sharing locked templates and holding short calibration meetings over video.
If internet access is intermittent, score offline and sync the final file later. HYPERLINK \l "fn73" \h [73] HYPERLINK \l "fn76" \h [76]
Training module outline
Module 1: What risk of bias means in trials and observational studies.
Module 2: Tool selection by study design.
Module 3: Domain-by-domain scoring practice.
Module 4: Disagreement resolution and adjudication.
Module 5: Converting judgments into figures and tables.
Module 6: Using RoB results in sensitivity analyses and GRADE. HYPERLINK \l "fn72" \h [72] HYPERLINK \l "fn71" \h [71]
Publication-ready summary
In the manuscript, summarize this section as: “Risk of bias was assessed independently by two reviewers using RoB 2 for randomized studies, ROBINS-I for nonrandomized interventions, NOS for cohort/case-control studies, and JBI checklists for descriptive designs. Disagreements were resolved by consensus or a third reviewer. Final judgments were visualized using traffic-light plots, domain summaries, and study-level tables.” HYPERLINK \l "fn77" \h [77] HYPERLINK \l "fn71" \h [71]
Timeline and go/no-go
Day 1: classify study designs and assign tools.
Day 2–3: calibrate on sample studies.
Day 4–10: complete independent scoring.
Day 11: adjudicate disagreements and lock final judgments.
Go: if all included studies have a completed tool and documented rationale.
No-go: if tool choice is inconsistent or calibration shows poor agreement; retrain before synthesis.
⁂
Real-world Implementation + Advanced Layers
Plan the quantitative synthesis for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Specify fixed-effect vs random-effects model (and why), pooled effect size calculation, heterogeneity stats (I², τ²), subgroup analyses, sensitivity analyses, and which forest / funnel plots you expect to generate. Turn the previous concept into an SOP-style procedure with step-by-step actions, responsible roles, minimum documentation required, and escalation triggers.
Plan the quantitative synthesis for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Specify fixed-effect vs random-effects model (and why), pooled effect size calculation, heterogeneity stats (I², τ²), subgroup analyses, sensitivity analyses, and which forest / funnel plots you expect to generate. Define quantitative quality indicators and thresholds that will prove this part of the study/review is working. Include how/when each metric is captured and who reviews it.
Plan the quantitative synthesis for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Specify fixed-effect vs random-effects model (and why), pooled effect size calculation, heterogeneity stats (I², τ²), subgroup analyses, sensitivity analyses, and which forest / funnel plots you expect to generate. Draft the patient/participant communication script or reviewer guidance text that should be read verbatim to maintain consistency and reduce bias.
Plan the quantitative synthesis for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Specify fixed-effect vs random-effects model (and why), pooled effect size calculation, heterogeneity stats (I², τ²), subgroup analyses, sensitivity analyses, and which forest / funnel plots you expect to generate. List foreseeable operational, ethical, or analytical failure modes in this part of the project and propose mitigation / contingency plans.
Plan the quantitative synthesis for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Specify fixed-effect vs random-effects model (and why), pooled effect size calculation, heterogeneity stats (I², τ²), subgroup analyses, sensitivity analyses, and which forest / funnel plots you expect to generate. Describe how this part of the project will be captured in regulatory or ethics submissions, including any appendices, audit trails, or notification requirements.
Plan the quantitative synthesis for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Specify fixed-effect vs random-effects model (and why), pooled effect size calculation, heterogeneity stats (I², τ²), subgroup analyses, sensitivity analyses, and which forest / funnel plots you expect to generate. Explain how digital tools, remote workflows, or decentralized methods will execute this part of the project in low-resource / community settings.
Plan the quantitative synthesis for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Specify fixed-effect vs random-effects model (and why), pooled effect size calculation, heterogeneity stats (I², τ²), subgroup analyses, sensitivity analyses, and which forest / funnel plots you expect to generate. Translate this part of the design into a training module outline for investigators, coordinators, community health workers, or evidence reviewers.
Plan the quantitative synthesis for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Specify fixed-effect vs random-effects model (and why), pooled effect size calculation, heterogeneity stats (I², τ²), subgroup analyses, sensitivity analyses, and which forest / funnel plots you expect to generate. Define how this part will be summarized in the final clinical study report or systematic review manuscript so it is publication-ready.
Plan the quantitative synthesis for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Specify fixed-effect vs random-effects model (and why), pooled effect size calculation, heterogeneity stats (I², τ²), subgroup analyses, sensitivity analyses, and which forest / funnel plots you expect to generate. Identify any data privacy, confidentiality, or IP considerations specific to this part, and describe safeguards.
Plan the quantitative synthesis for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Specify fixed-effect vs random-effects model (and why), pooled effect size calculation, heterogeneity stats (I², τ²), subgroup analyses, sensitivity analyses, and which forest / funnel plots you expect to generate. Propose timeline checkpoints, gating criteria, and go/no-go decisions specifically for this part before advancing to the next phase.
Describe how you'll assess publication bias and selective reporting in this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Include funnel plot asymmetry, Egger’s regression, trim-and-fill, and leave-one-out tests to check robustness.
Describe how you'll assess publication bias and selective reporting in this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Include funnel plot asymmetry, Egger’s regression, trim-and-fill, and leave-one-out tests to check robustness. Turn the previous concept into an SOP-style procedure with step-by-step actions, responsible roles, minimum documentation required, and escalation triggers.
Describe how you'll assess publication bias and selective reporting in this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Include funnel plot asymmetry, Egger’s regression, trim-and-fill, and leave-one-out tests to check robustness. Define quantitative quality indicators and thresholds that will prove this part of the study/review is working. Include how/when each metric is captured and who reviews it.
Describe how you'll assess publication bias and selective reporting in this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Include funnel plot asymmetry, Egger’s regression, trim-and-fill, and leave-one-out tests to check robustness. Draft the patient/participant communication script or reviewer guidance text that should be read verbatim to maintain consistency and reduce bias.
Describe how you'll assess publication bias and selective reporting in this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Include funnel plot asymmetry, Egger’s regression, trim-and-fill, and leave-one-out tests to check robustness. List foreseeable operational, ethical, or analytical failure modes in this part of the project and propose mitigation / contingency plans.
Describe how you'll assess publication bias and selective reporting in this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Include funnel plot asymmetry, Egger’s regression, trim-and-fill, and leave-one-out tests to check robustness. Describe how this part of the project will be captured in regulatory or ethics submissions, including any appendices, audit trails, or notification requirements.
Describe how you'll assess publication bias and selective reporting in this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Include funnel plot asymmetry, Egger’s regression, trim-and-fill, and leave-one-out tests to check robustness. Explain how digital tools, remote workflows, or decentralized methods will execute this part of the project in low-resource / community settings.
Describe how you'll assess publication bias and selective reporting in this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Include funnel plot asymmetry, Egger’s regression, trim-and-fill, and leave-one-out tests to check robustness. Translate this part of the design into a training module outline for investigators, coordinators, community health workers, or evidence reviewers.
Describe how you'll assess publication bias and selective reporting in this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Include funnel plot asymmetry, Egger’s regression, trim-and-fill, and leave-one-out tests to check robustness. Define how this part will be summarized in the final clinical study report or systematic review manuscript so it is publication-ready.
Describe how you'll assess publication bias and selective reporting in this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Include funnel plot asymmetry, Egger’s regression, trim-and-fill, and leave-one-out tests to check robustness. Identify any data privacy, confidentiality, or IP considerations specific to this part, and describe safeguards.
Describe how you'll assess publication bias and selective reporting in this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Include funnel plot asymmetry, Egger’s regression, trim-and-fill, and leave-one-out tests to check robustness. Propose timeline checkpoints, gating criteria, and go/no-go decisions specifically for this part before advancing to the next phase.
Write the final reporting and interpretation plan for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Summarize PRISMA reporting elements, GRADE evidence profiles, strength/limitations of the body of evidence, and implications for clinical practice and future research.
Write the final reporting and interpretation plan for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Summarize PRISMA reporting elements, GRADE evidence profiles, strength/limitations of the body of evidence, and implications for clinical practice and future research. Turn the previous concept into an SOP-style procedure with step-by-step actions, responsible roles, minimum documentation required, and escalation triggers.
Write the final reporting and interpretation plan for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Summarize PRISMA reporting elements, GRADE evidence profiles, strength/limitations of the body of evidence, and implications for clinical practice and future research. Define quantitative quality indicators and thresholds that will prove this part of the study/review is working. Include how/when each metric is captured and who reviews it.
Write the final reporting and interpretation plan for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Summarize PRISMA reporting elements, GRADE evidence profiles, strength/limitations of the body of evidence, and implications for clinical practice and future research. Draft the patient/participant communication script or reviewer guidance text that should be read verbatim to maintain consistency and reduce bias.
Write the final reporting and interpretation plan for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Summarize PRISMA reporting elements, GRADE evidence profiles, strength/limitations of the body of evidence, and implications for clinical practice and future research. List foreseeable operational, ethical, or analytical failure modes in this part of the project and propose mitigation / contingency plans.
Write the final reporting and interpretation plan for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Summarize PRISMA reporting elements, GRADE evidence profiles, strength/limitations of the body of evidence, and implications for clinical practice and future research. Describe how this part of the project will be captured in regulatory or ethics submissions, including any appendices, audit trails, or notification requirements.
Write the final reporting and interpretation plan for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Summarize PRISMA reporting elements, GRADE evidence profiles, strength/limitations of the body of evidence, and implications for clinical practice and future research. Explain how digital tools, remote workflows, or decentralized methods will execute this part of the project in low-resource / community settings.
Write the final reporting and interpretation plan for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Summarize PRISMA reporting elements, GRADE evidence profiles, strength/limitations of the body of evidence, and implications for clinical practice and future research. Translate this part of the design into a training module outline for investigators, coordinators, community health workers, or evidence reviewers.
Write the final reporting and interpretation plan for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Summarize PRISMA reporting elements, GRADE evidence profiles, strength/limitations of the body of evidence, and implications for clinical practice and future research. Define how this part will be summarized in the final clinical study report or systematic review manuscript so it is publication-ready.
Write the final reporting and interpretation plan for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Summarize PRISMA reporting elements, GRADE evidence profiles, strength/limitations of the body of evidence, and implications for clinical practice and future research. Identify any data privacy, confidentiality, or IP considerations specific to this part, and describe safeguards.
Write the final reporting and interpretation plan for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Summarize PRISMA reporting elements, GRADE evidence profiles, strength/limitations of the body of evidence, and implications for clinical practice and future research. Propose timeline checkpoints, gating criteria, and go/no-go decisions specifically for this part before advancing to the next phase.
Write the final reporting and interpretation plan for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Summarize PRISMA reporting elements, GRADE evidence profiles, strength/limitations of the body of evidence, and implications for clinical practice and future research. Identify any data privacy, confidentiality, or IP considerations specific to this part, and describe safeguards.
Write the final reporting and interpretation plan for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Summarize PRISMA reporting elements, GRADE evidence profiles, strength/limitations of the body of evidence, and implications for clinical practice and future research. Propose timeline checkpoints, gating criteria, and go/no-go decisions specifically for this part before advancing to the next phase.
Write the final reporting and interpretation plan for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Summarize PRISMA reporting elements, GRADE evidence profiles, strength/limitations of the body of evidence, and implications for clinical practice and future research. Turn the previous concept into an SOP-style procedure with step-by-step actions, responsible roles, minimum documentation required, and escalation triggers.
Write the final reporting and interpretation plan for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Summarize PRISMA reporting elements, GRADE evidence profiles, strength/limitations of the body of evidence, and implications for clinical practice and future research. Define quantitative quality indicators and thresholds that will prove this part of the study/review is working. Include how/when each metric is captured and who reviews it.
Write the final reporting and interpretation plan for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Summarize PRISMA reporting elements, GRADE evidence profiles, strength/limitations of the body of evidence, and implications for clinical practice and future research. Draft the patient/participant communication script or reviewer guidance text that should be read verbatim to maintain consistency and reduce bias.
Write the final reporting and interpretation plan for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Summarize PRISMA reporting elements, GRADE evidence profiles, strength/limitations of the body of evidence, and implications for clinical practice and future research. List foreseeable operational, ethical, or analytical failure modes in this part of the project and propose mitigation / contingency plans.
Write the final reporting and interpretation plan for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Summarize PRISMA reporting elements, GRADE evidence profiles, strength/limitations of the body of evidence, and implications for clinical practice and future research. Describe how this part of the project will be captured in regulatory or ethics submissions, including any appendices, audit trails, or notification requirements.
Write the final reporting and interpretation plan for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Summarize PRISMA reporting elements, GRADE evidence profiles, strength/limitations of the body of evidence, and implications for clinical practice and future research. Explain how digital tools, remote workflows, or decentralized methods will execute this part of the project in low-resource / community settings.
Write the final reporting and interpretation plan for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Summarize PRISMA reporting elements, GRADE evidence profiles, strength/limitations of the body of evidence, and implications for clinical practice and future research. Translate this part of the design into a training module outline for investigators, coordinators, community health workers, or evidence reviewers.
Write the final reporting and interpretation plan for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Summarize PRISMA reporting elements, GRADE evidence profiles, strength/limitations of the body of evidence, and implications for clinical practice and future research. Define how this part will be summarized in the final clinical study report or systematic review manuscript so it is publication-ready.
Write the final reporting and interpretation plan for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Summarize PRISMA reporting elements, GRADE evidence profiles, strength/limitations of the body of evidence, and implications for clinical practice and future research. Identify any data privacy, confidentiality, or IP considerations specific to this part, and describe safeguards.
Write the final reporting and interpretation plan for this same systematic review and meta-analysis on oral cancer using Chlorophyll/Chlorophyllin, Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid oral strip. Summarize PRISMA reporting elements, GRADE evidence profiles, strength/limitations of the body of evidence, and implications for clinical practice and future research. Propose timeline checkpoints, gating criteria, and go/no-go decisions specifically for this part before advancing to the next phase.
Use a random-effects model as the default for this review, with fixed-effect analyses as sensitivity checks only. That is the safer choice because these phytochemicals, dose forms, populations, and outcome types are likely to vary across studies, so the review should estimate an average effect across a distribution of true effects rather than assume one common effect. HYPERLINK \l "fn88" \h [88] HYPERLINK \l "fn89" \h [89]
Synthesis model
Primary model: random-effects meta-analysis.
Sensitivity model: fixed-effect meta-analysis when studies are highly similar in design, population, intervention, and outcome definition.
Why: the review will likely combine heterogeneous evidence across compounds, delivery formats, and study designs; random-effects better reflects between-study variability. Cochrane guidance emphasizes careful consideration of heterogeneity rather than using a single rigid rule. HYPERLINK \l "fn89" \h [89] HYPERLINK \l "fn90" \h [90] HYPERLINK \l "fn88" \h [88]
Practical rule: if the number of studies in a subgroup is very small or clinical heterogeneity is extreme, do not force pooling; use narrative synthesis. HYPERLINK \l "fn91" \h [91] HYPERLINK \l "fn88" \h [88]
Effect sizes
Continuous outcomes: use mean difference when all studies use the same scale; otherwise use standardized mean difference with Hedges’ g.
Dichotomous outcomes: use risk ratio for common clinical endpoints, or odds ratio if that is what the studies report consistently.
Time-to-event outcomes: use hazard ratio if available.
Biomarker outcomes: pool on the same assay/scale only if units are harmonized; otherwise standardize.
Extract or convert effect sizes with 95% confidence intervals, then enter them into a single analysis dataset for each outcome family. HYPERLINK \l "fn88" \h [88] HYPERLINK \l "fn91" \h [91]
Heterogeneity
Report Cochran’s Q, I², and τ² for every pooled analysis.
Use I² as a descriptive indicator of inconsistency, but do not use it alone to decide whether pooling is “allowed.”
Use τ² as the primary estimate of between-study variance because it is the variance component in random-effects models and is less misleading than relying on I² alone. HYPERLINK \l "fn92" \h [92] HYPERLINK \l "fn93" \h [93] HYPERLINK \l "fn90" \h [90]
If I² is moderate to high or τ² is nontrivial, explore reasons through subgroup and sensitivity analysis rather than over-interpreting a single pooled estimate. HYPERLINK \l "fn91" \h [91] HYPERLINK \l "fn88" \h [88]
Subgroups
Pre-specify subgroups to avoid data dredging:
Compound: chlorophyll/chlorophyllin vs apigenin/flavonoids vs rutin/quercetin vs abscisic acid.
Formulation: oral strip/film/lozenge vs other local delivery vs systemic.
Population: OPMD vs confirmed OSCC.
Design: randomized vs nonrandomized vs preclinical/translational.
Dose/duration: low vs high dose, short vs longer follow-up.
Risk of bias: low/moderate vs high risk.Subgroup effects should be interpreted cautiously and only when there are enough studies per subgroup to be meaningful. HYPERLINK \l "fn89" \h [89] HYPERLINK \l "fn88" \h [88]
Sensitivity analyses
Remove studies at high risk of bias.
Remove one study at a time (leave-one-out) to test robustness.
Compare random-effects with fixed-effect estimates.
Repeat analyses excluding abstracts, preprints, or non-peer-reviewed records.
Repeat with alternative effect-size assumptions if a study reports medians, transformed outcomes, or imputed variances.If a result changes direction or loses significance after any of these checks, treat the pooled estimate as unstable. HYPERLINK \l "fn94" \h [94] HYPERLINK \l "fn88" \h [88]
Publication bias and selective reporting
Use funnel plots only when there are enough studies for the plot to be interpretable; with too few studies, asymmetry is hard to judge reliably.
Run Egger’s regression for small-study effects when there are sufficient studies in a comparison.
Use trim-and-fill as an exploratory adjustment, not as a definitive correction.
Perform leave-one-out analyses to identify influential studies and determine whether one study drives the result.
Compare published outcomes against protocol/registry records when available to detect selective reporting. HYPERLINK \l "fn95" \h [95] HYPERLINK \l "fn94" \h [94]
Expected plots
Forest plot for each primary outcome and each major subgroup.
Forest plot for sensitivity analyses.
Funnel plot for outcomes with enough studies.
Influence plot or leave-one-out plot if the software supports it.
Bias-profile summary figure from the risk-of-bias assessment. HYPERLINK \l "fn96" \h [96] HYPERLINK \l "fn88" \h [88]
SOP procedure
Step 1: Prepare analysis dataset
Action: Clean the extraction sheet, harmonize units, and define one effect size per study per outcome.
Role: Statistician and data manager.
Docs: locked analysis dataset, codebook, transformation log.
Escalation: if the same outcome is reported in incompatible ways, decide whether to standardize or narratively synthesize.
Step 2: Choose effect metric
Action: Assign MD, SMD, RR, OR, or HR by outcome type.
Role: Statistician.
Docs: metric decision log.
Escalation: ambiguous metrics go to the methodologist.
Step 3: Run primary meta-analysis
Action: Fit random-effects model for each outcome family.
Role: Statistician.
Docs: model output, forest plot, heterogeneity stats.
Escalation: if pooling assumptions are weak, stop and switch to narrative synthesis.
Step 4: Run heterogeneity checks
Action: Record Q, I², τ², and inspect outliers.
Role: Statistician and methodologist.
Docs: heterogeneity table, outlier notes.
Escalation: unexplained high heterogeneity triggers subgroup analysis.
Step 5: Run sensitivity and bias checks
Action: Do leave-one-out, fixed-effect comparison, and publication-bias analyses when feasible.
Role: Statistician.
Docs: sensitivity report, funnel plot, Egger output, trim-and-fill output.
Escalation: unstable findings require cautious interpretation and downgraded certainty.
Step 6: Lock results
Action: Finalize pooled estimates and figures for reporting.
Role: PI and statistician.
Docs: final model file, figure set, result summary.
Escalation: any post-lock changes require version control and justification.
Quality indicators
Model pre-specification: 100% of outcomes assigned a model before analysis begins.
Effect-size completeness: ≥90% of eligible studies contribute analyzable effect estimates.
Heterogeneity reporting: Q, I², and τ² reported for every pooled estimate.
Sensitivity coverage: leave-one-out and fixed-vs-random comparison completed for all key outcomes.
Bias diagnostics: funnel/Egger/trim-and-fill performed whenever study count is sufficient.Captured after each outcome family is analyzed and reviewed by the statistician and PI. HYPERLINK \l "fn93" \h [93] HYPERLINK \l "fn88" \h [88]
Verbatim reviewer guidance
“Use the effect size and model specified in the protocol. Do not switch models after seeing the result unless the pre-specified criteria are met and the change is documented. If heterogeneity is high, explore it systematically instead of forcing a single pooled estimate. Treat publication-bias tests as exploratory and interpret them in context.” HYPERLINK \l "fn94" \h [94] HYPERLINK \l "fn88" \h [88]
Failure modes and mitigations
Too few studies: do not overstate pooled estimates; use narrative synthesis.
Mixed outcome scales: standardize or stratify before pooling.
Extreme heterogeneity: subgroup or avoid pooling.
Small-study effects: report funnel asymmetry and sensitivity results transparently.
Selective reporting: cross-check registry/protocol records where available. HYPERLINK \l "fn95" \h [95] HYPERLINK \l "fn94" \h [94]
Reporting and interpretation
In the manuscript, report the model choice, pooled estimate, effect-size metric, heterogeneity statistics, subgroup analyses, sensitivity analyses, and publication-bias diagnostics.
In GRADE, downgrade certainty for high risk of bias, inconsistency, indirectness, imprecision, and publication bias where applicable.
State clearly that the most likely interpretation for this topic is supportive but preliminary unless several consistent, low-bias human studies are available. HYPERLINK \l "fn97" \h [97] HYPERLINK \l "fn88" \h [88]
Timeline and go/no-go
Day 1–2: finalize analysis plan and outcome families.
Day 3–5: build analysis dataset.
Day 6–10: run primary meta-analyses and heterogeneity checks.
Day 11–14: run sensitivity, subgroup, and publication-bias analyses.
Go: if at least one key outcome has sufficient comparable studies and the model assumptions are documented.
No-go: if outcomes are too sparse or inconsistent to pool without misleading interpretation.
⁂

HYPERLINK "https://libguides.wvu.edu/SystematicReviews/PICO" \h https://libguides.wvu.edu/SystematicReviews/PICO      
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC11854426/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC11854426/   
 HYPERLINK "https://www.perplexity.ai/search/bf3dce75-1ac6-4471-9138-09bd88151d2c" \h https://www.perplexity.ai/search/bf3dce75-1ac6-4471-9138-09bd88151d2c  
 HYPERLINK "https://www.perplexity.ai/search/2bffbe48-08ae-41d8-ade7-03b04cd780d5" \h https://www.perplexity.ai/search/2bffbe48-08ae-41d8-ade7-03b04cd780d5  
 HYPERLINK "https://www.perplexity.ai/search/57b3bcce-9abf-4e35-a491-4fdb98c92579" \h https://www.perplexity.ai/search/57b3bcce-9abf-4e35-a491-4fdb98c92579 
 HYPERLINK "https://www.perplexity.ai/search/5ed84cae-e1a9-412d-a769-be7ad5ea35df" \h https://www.perplexity.ai/search/5ed84cae-e1a9-412d-a769-be7ad5ea35df   
 HYPERLINK "https://www.ilcor.org/data/PROSPERORegistration.pdf" \h https://www.ilcor.org/data/PROSPERORegistration.pdf 
 HYPERLINK "https://www.ilcor.org/uploads/Systematic-Review-PROSPERO-registration-template-SAC-approved-v2.0-7-January-2022.docx" \h https://www.ilcor.org/uploads/Systematic-Review-PROSPERO-registration-template-SAC-approved-v2.0-7-January-2022.docx 
 HYPERLINK "https://www.cochranelibrary.com/about-pico" \h https://www.cochranelibrary.com/about-pico   
 HYPERLINK "https://researchgold.org/resources/pico-framework-builder" \h https://researchgold.org/resources/pico-framework-builder 
 HYPERLINK "https://libguides.ntu.edu.sg/c.php?g=936042&p=6768649" \h https://libguides.ntu.edu.sg/c.php?g=936042&p=6768649 
paste.txt 
 HYPERLINK "https://www.ncbi.nlm.nih.gov/books/NBK44075/table/A29833/" \h https://www.ncbi.nlm.nih.gov/books/NBK44075/table/A29833/ 
 HYPERLINK "https://www.library.sydney.edu.au/support/searching/pico" \h https://www.library.sydney.edu.au/support/searching/pico 
 HYPERLINK "https://www.nature.com/articles/s41432-022-0235-1" \h https://www.nature.com/articles/s41432-022-0235-1 
 HYPERLINK "https://d-nb.info/1114353914/34" \h https://d-nb.info/1114353914/34 
 HYPERLINK "https://libguides.lb.polyu.edu.hk/syst_review/PICO" \h https://libguides.lb.polyu.edu.hk/syst_review/PICO 
 HYPERLINK "https://www.cdc.gov/acip-grade-handbook/hcp/chapter-4-formulating-pico-questions/index.html" \h https://www.cdc.gov/acip-grade-handbook/hcp/chapter-4-formulating-pico-questions/index.html 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC9054164/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC9054164/ 
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/26693826/" \h https://pubmed.ncbi.nlm.nih.gov/26693826/ 
 HYPERLINK "https://www.bmj.com/content/372/bmj.n71" \h https://www.bmj.com/content/372/bmj.n71      
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC7839230/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC7839230/       
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC4619264/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC4619264/   
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/25364656/" \h https://pubmed.ncbi.nlm.nih.gov/25364656/   
 HYPERLINK "https://library-guides.imperial.ac.uk/systematic-review/using_greyliterature" \h https://library-guides.imperial.ac.uk/systematic-review/using_greyliterature      
 HYPERLINK "https://mdanderson.libguides.com/c.php?g=384755&p=2608640" \h https://mdanderson.libguides.com/c.php?g=384755&p=2608640  
 HYPERLINK "https://libguides.wvu.edu/SystematicReviews/PICO" \h https://libguides.wvu.edu/SystematicReviews/PICO 
 HYPERLINK "https://unimelb.libguides.com/greylithealth/reviews" \h https://unimelb.libguides.com/greylithealth/reviews 
 HYPERLINK "https://asklib.hsl.unc.edu/faq/370028" \h https://asklib.hsl.unc.edu/faq/370028 
 HYPERLINK "https://libguides.kcl.ac.uk/systematicreview/recording" \h https://libguides.kcl.ac.uk/systematicreview/recording 
 HYPERLINK "https://guides.lib.unc.edu/grey-literature/systematic-reviews" \h https://guides.lib.unc.edu/grey-literature/systematic-reviews 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC9798848/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC9798848/ 
 HYPERLINK "https://www.elifecycle.org/archive/view_article?pid=lc-2-0-9" \h https://www.elifecycle.org/archive/view_article?pid=lc-2-0-9 
 HYPERLINK "https://guides.lib.unc.edu/systematic-reviews/write" \h https://guides.lib.unc.edu/systematic-reviews/write 
 HYPERLINK "https://oercollective.caul.edu.au/scoping-systematic-reviews/chapter/comprehensive-search/" \h https://oercollective.caul.edu.au/scoping-systematic-reviews/chapter/comprehensive-search/ 
 HYPERLINK "https://door.donau-uni.ac.at/api/object/o:6018/get" \h https://door.donau-uni.ac.at/api/object/o:6018/get 
 HYPERLINK "https://www.prisma-statement.org/prisma-2020-flow-diagram" \h https://www.prisma-statement.org/prisma-2020-flow-diagram      
 HYPERLINK "https://musc.libguides.com/systematicreviews/screening" \h https://musc.libguides.com/systematicreviews/screening      
 HYPERLINK "https://guides.lib.umich.edu/c.php?g=283340&p=8806680&rut=c49011c176ee1929ee4473b359c126743f6a4be9d1d75ed496238c09f5032b45" \h https://guides.lib.umich.edu/c.php?g=283340&p=8806680&rut=c49011c176ee1929ee4473b359c126743f6a4be9d1d75ed496238c09f5032b45        
 HYPERLINK "https://guides.hsict.library.utoronto.ca/c.php?g=699108&p=4964044" \h https://guides.hsict.library.utoronto.ca/c.php?g=699108&p=4964044      
 HYPERLINK "https://libguides.mq.edu.au/systematic_reviews/prisma_screen" \h https://libguides.mq.edu.au/systematic_reviews/prisma_screen      
 HYPERLINK "https://libguides.vu.nl/SystematicReviews/select" \h https://libguides.vu.nl/SystematicReviews/select    
 HYPERLINK "https://guides.mclibrary.duke.edu/sysreview/screen" \h https://guides.mclibrary.duke.edu/sysreview/screen    
 HYPERLINK "https://link.springer.com/article/10.1186/s12874-019-0782-0" \h https://link.springer.com/article/10.1186/s12874-019-0782-0 
 HYPERLINK "https://www.prisma-statement.org/prisma-2020" \h https://www.prisma-statement.org/prisma-2020   
 HYPERLINK "https://guides.library.ulster.ac.uk/LHS/evidence/PRISMA" \h https://guides.library.ulster.ac.uk/LHS/evidence/PRISMA 
 HYPERLINK "https://cdn-links.lww.com/permalink/js9/a/js9_2023_05_08_chen_ijs-d-22-01818r3_sdc1.pdf" \h https://cdn-links.lww.com/permalink/js9/a/js9_2023_05_08_chen_ijs-d-22-01818r3_sdc1.pdf 
 HYPERLINK "https://eppi.ioe.ac.uk/CMS/Portals/0/Study%20Selection%20-%20Andrew%20Booth%20-%20ESG.pdf" \h https://eppi.ioe.ac.uk/CMS/Portals/0/Study Selection - Andrew Booth - ESG.pdf 
 HYPERLINK "https://www.bmj.com/content/372/bmj.n71" \h https://www.bmj.com/content/372/bmj.n71 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC7839230/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC7839230/ 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC8005925/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC8005925/ 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC12962141/figure/f0005/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC12962141/figure/f0005/ 
 HYPERLINK "https://uws-uk.libguides.com/c.php?g=729443&p=5315762" \h https://uws-uk.libguides.com/c.php?g=729443&p=5315762 
 HYPERLINK "https://www.ncbi.nlm.nih.gov/books/NBK559559/" \h https://www.ncbi.nlm.nih.gov/books/NBK559559/ 
 HYPERLINK "https://guides.lib.unc.edu/prisma" \h https://guides.lib.unc.edu/prisma 
 HYPERLINK "https://guides.libraries.emory.edu/CVP_scoping/prisma" \h https://guides.libraries.emory.edu/CVP_scoping/prisma 
 HYPERLINK "https://www.covidence.org/wp-content/uploads/2025/04/A-practical-guide-Screening-for-Systematic-Reviews.pdf" \h https://www.covidence.org/wp-content/uploads/2025/04/A-practical-guide-Screening-for-Systematic-Reviews.pdf 
 HYPERLINK "https://elicit.com/blog/systematic-review-for-prisma-2020" \h https://elicit.com/blog/systematic-review-for-prisma-2020 
 HYPERLINK "https://www.sciencedirect.com/science/article/pii/S1743919121000522" \h https://www.sciencedirect.com/science/article/pii/S1743919121000522 
 HYPERLINK "https://library.ukzn.ac.za/wp-content/uploads/2025/05/A-practical-guide-Screening-for-Systematic-Reviews-002.pdf" \h https://library.ukzn.ac.za/wp-content/uploads/2025/05/A-practical-guide-Screening-for-Systematic-Reviews-002.pdf 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC6989049/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC6989049/ 
 HYPERLINK "https://fr.slideshare.net/slideshow/screening-and-selecting-studies-for-systematic-review-dr-reginald-quansah/284281382" \h https://fr.slideshare.net/slideshow/screening-and-selecting-studies-for-systematic-review-dr-reginald-quansah/284281382 
 HYPERLINK "https://researchgold.org/blog/second-reviewer-systematic-review-screening" \h https://researchgold.org/blog/second-reviewer-systematic-review-screening 
 HYPERLINK "https://www.cochrane.org/authors/handbooks-and-manuals/cochrane-handbook-systematic-reviews-prognosis-research-and-prediction-models/prognosis-handbook-chapter-7-selection-and-inclusion-studies" \h https://www.cochrane.org/authors/handbooks-and-manuals/cochrane-handbook-systematic-reviews-prognosis-research-and-prediction-models/prognosis-handbook-chapter-7-selection-and-inclusion-studies 
 HYPERLINK "https://www.youtube.com/watch?v=cPpKc2b1_ug" \h https://www.youtube.com/watch?v=cPpKc2b1_ug 
 HYPERLINK "https://scispace.com/ai-agent-seo/page-files/percent-agreement-screening-evidence-irp5njzh.pdf" \h https://scispace.com/ai-agent-seo/page-files/percent-agreement-screening-evidence-irp5njzh.pdf 
 HYPERLINK "https://www.ncbi.nlm.nih.gov/books/NBK97420/" \h https://www.ncbi.nlm.nih.gov/books/NBK97420/ 
 HYPERLINK "https://d-nb.info/1197752226/34" \h https://d-nb.info/1197752226/34 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC8005925/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC8005925/          
 HYPERLINK "https://www.prisma-statement.org/prisma-2020-flow-diagram" \h https://www.prisma-statement.org/prisma-2020-flow-diagram       
 HYPERLINK "https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials" \h https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials        
 HYPERLINK "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-25" \h https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-25    
 HYPERLINK "https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-019-1172-8/tables/3" \h https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-019-1172-8/tables/3   
 HYPERLINK "https://sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool" \h https://sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool 
 HYPERLINK "https://www.cochrane.org/learn/courses-and-resources/cochrane-methodology/risk-bias" \h https://www.cochrane.org/learn/courses-and-resources/cochrane-methodology/risk-bias 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC12554380/table/TAB2/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC12554380/table/TAB2/   
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC8005925/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC8005925/   
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/34002466/" \h https://pubmed.ncbi.nlm.nih.gov/34002466/  
 HYPERLINK "https://www.prisma-statement.org/prisma-2020-flow-diagram" \h https://www.prisma-statement.org/prisma-2020-flow-diagram 
 HYPERLINK "https://methods.cochrane.org/bias/news/rob-2-tool" \h https://methods.cochrane.org/bias/news/rob-2-tool 
 HYPERLINK "https://www.cochrane.de/sites/cochrane.de/files/uploads/workshop/Lunch%20AND%20Learn/RoB_2.0_guidance_2019.pdf" \h https://www.cochrane.de/sites/cochrane.de/files/uploads/workshop/Lunch AND Learn/RoB_2.0_guidance_2019.pdf 
 HYPERLINK "https://methods.cochrane.org/file/rob-2-starter-pack-cochrane-reviewspdf" \h https://methods.cochrane.org/file/rob-2-starter-pack-cochrane-reviewspdf 
 HYPERLINK "https://www.ncbi.nlm.nih.gov/books/NBK621329/" \h https://www.ncbi.nlm.nih.gov/books/NBK621329/ 
 HYPERLINK "https://www.cochrane.org/de/learn/courses-and-resources/cochrane-methodology/risk-bias/about-risk-bias-2-rob-2" \h https://www.cochrane.org/de/learn/courses-and-resources/cochrane-methodology/risk-bias/about-risk-bias-2-rob-2 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC11147813/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC11147813/ 
 HYPERLINK "https://methods.cochrane.org/sites/methods.cochrane.org.bias/files/uploads/announcement_-" \h https://methods.cochrane.org/sites/methods.cochrane.org.bias/files/uploads/announcement_-new_risk_of_bias_tools-_cochrane_seoul.pdf 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC6857304/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC6857304/ 
 HYPERLINK "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-10" \h https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-10           
 HYPERLINK "https://www.cochrane.org/sites/default/files/uploads/PDFs/Methods%20reports/2025/Spotlight%20On_SMG.pdf" \h https://www.cochrane.org/sites/default/files/uploads/PDFs/Methods reports/2025/Spotlight On_SMG.pdf   
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC2648991/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC2648991/  
 HYPERLINK "https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/ehc-presentation-quantitative-synthesis-chapter-4.pdf" \h https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/ehc-presentation-quantitative-synthesis-chapter-4.pdf   
 HYPERLINK "https://abstracts.cochrane.org/2008-freiburg/heterogeneity-meta-analysis-misconceiving-i2" \h https://abstracts.cochrane.org/2008-freiburg/heterogeneity-meta-analysis-misconceiving-i2 
 HYPERLINK "https://abstracts.cochrane.org/2024-prague-global-evidence-summit/assessing-heterogeneity-meta-analysis-what-q-i2-tau2-and" \h https://abstracts.cochrane.org/2024-prague-global-evidence-summit/assessing-heterogeneity-meta-analysis-what-q-i2-tau2-and  
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC6571372/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC6571372/    
 HYPERLINK "https://www.bmj.com/content/372/bmj.n71" \h https://www.bmj.com/content/372/bmj.n71  
 HYPERLINK "https://www.prisma-statement.org/prisma-2020-flow-diagram" \h https://www.prisma-statement.org/prisma-2020-flow-diagram 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC8005925/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC8005925/ 
 HYPERLINK "https://stat.ethz.ch/pipermail/r-sig-meta-analysis/2021-October/003447.html" \h https://stat.ethz.ch/pipermail/r-sig-meta-analysis/2021-October/003447.html 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC9843903/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC9843903/ 
 HYPERLINK "https://www.scribd.com/document/916958730/Handling-heterogeneity-in-Cochrane-reviews" \h https://www.scribd.com/document/916958730/Handling-heterogeneity-in-Cochrane-reviews 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC12779580/table/TAB11/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC12779580/table/TAB11/ 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC3405079/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC3405079/ 
 HYPERLINK "https://scholarworks.wmich.edu/cgi/viewcontent.cgi?article=4933&context=dissertations" \h https://scholarworks.wmich.edu/cgi/viewcontent.cgi?article=4933&context=dissertations 
 HYPERLINK "https://www.ssph-journal.org/journals/public-health-reviews/articles/10.3389/phrs.2023.1605454/rrpt/phrs-44-1605454-r3/reviewer_3_report_v1.pdf" \h https://www.ssph-journal.org/journals/public-health-reviews/articles/10.3389/phrs.2023.1605454/rrpt/phrs-44-1605454-r3/reviewer_3_report_v1.pdf 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC12485469/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC12485469/

Your AI API key

This is used only to analyse this document and is kept only in your current browser session on this server - it is never written to a file, never sent to the page's JavaScript, and never shown to anyone else. Get a key at openrouter.ai/keys.

You are responsible for your own AI provider usage costs. Requests made with your key are billed by your provider (e.g. OpenRouter) to your account, at their normal rates - this site does not charge you separately and cannot see or control your provider's pricing.

Skip to the existing review table →